

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding and managing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-2097/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-2097" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding and managing pediatric inflammatory bowel disease" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding and managing pediatric inflammatory bowel disease.">
            <meta name="og:description" content="Read the latest article version by Bhaskar Gurram, Ashish S. Patel, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="21500">
            <meta name="article-id" content="19609">
            <meta name="dc.title" content="Recent advances in understanding and managing pediatric inflammatory bowel disease">
            <meta name="dc.description" content="The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. By reviewing epidemiology, pathophysiology, and goals of treatment, we hope to frame the discussion of current and novel therapeutics for the pediatric gastroenterologist. As scientific discovery continues to push the envelope in defining our understanding of pediatric inflammatory bowel disease, the current era of therapeutics gives us hope that a cure may be realized soon.">
            <meta name="dc.subject" content="pediatric inflammatory bowel disease, Crohn&rsquo;s disease, ulcerative colitis">
            <meta name="dc.creator" content="Gurram, Bhaskar">
            <meta name="dc.creator" content="Patel, Ashish S.">
            <meta name="dc.date" content="2019/12/13">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19609.1">
            <meta name="dc.source" content="F1000Research 2019 8:2097">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="pediatric inflammatory bowel disease">
            <meta name="prism.keyword" content="Crohn&rsquo;s disease">
            <meta name="prism.keyword" content="ulcerative colitis">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/12/13">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="2097">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19609.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-2097">
            <meta name="citation_title" content="Recent advances in understanding and managing pediatric inflammatory bowel disease">
            <meta name="citation_abstract" content="The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. By reviewing epidemiology, pathophysiology, and goals of treatment, we hope to frame the discussion of current and novel therapeutics for the pediatric gastroenterologist. As scientific discovery continues to push the envelope in defining our understanding of pediatric inflammatory bowel disease, the current era of therapeutics gives us hope that a cure may be realized soon.">
            <meta name="citation_description" content="The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. By reviewing epidemiology, pathophysiology, and goals of treatment, we hope to frame the discussion of current and novel therapeutics for the pediatric gastroenterologist. As scientific discovery continues to push the envelope in defining our understanding of pediatric inflammatory bowel disease, the current era of therapeutics gives us hope that a cure may be realized soon.">
            <meta name="citation_keywords" content="pediatric inflammatory bowel disease, Crohn&rsquo;s disease, ulcerative colitis">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Bhaskar Gurram">
            <meta name="citation_author_institution" content="University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA">
            <meta name="citation_author" content="Ashish S. Patel">
            <meta name="citation_author_institution" content="University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA">
            <meta name="citation_publication_date" content="2019/12/13">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="2097">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19609.1">
            <meta name="citation_firstpage" content="2097">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-2097/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-2097.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=21500 /> <input type=hidden id=articleId name=articleId value=19609 /> <input type=hidden id=xmlUrl value="/articles/8-2097/v1/xml"/> <input type=hidden id=xmlFileName value="-8-2097-v1.xml"> <input type=hidden id=article_uuid value=03cdc746-d4bb-4805-a109-536e81f749e6 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding and managing pediatric inflammatory bowel disease"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19609.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19609.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-2097"
  },
  "headline": "Recent advances in understanding and managing pediatric inflammatory bowel disease",
  "datePublished": "2019-12-13T10:48:50",
  "dateModified": "2019-12-13T10:48:50",
  "author": [
    {
      "@type": "Person",
      "name": "Bhaskar Gurram"
    },    {
      "@type": "Person",
      "name": "Ashish S. Patel"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. By reviewing epidemiology, pathophysiology, and goals of treatment, we hope to frame the discussion of current and novel therapeutics for the pediatric gastroenterologist. As scientific discovery continues to push the envelope in defining our understanding of pediatric inflammatory bowel disease, the current era of therapeutics gives us hope that a cure may be realized soon."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-2097/v1",
            "name": "Recent advances in understanding and managing pediatric inflammatory..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding and managing pediatric inflammatory... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=21500 data-id=19609 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19609.1" data-recommended="" data-doi="10.12688/f1000research.19609.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-2097/v1/pdf?article_uuid=03cdc746-d4bb-4805-a109-536e81f749e6" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19609-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19609-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19609-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Gurram B and Patel AS. Recent advances in understanding and managing pediatric inflammatory bowel disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2097 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19609.1" target=_blank>https://doi.org/10.12688/f1000research.19609.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19609-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19609 id=track-article-signin-19609 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19609?target=/articles/8-2097/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21500 /> <input name=articleId type=hidden value=19609 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding and managing pediatric inflammatory bowel disease</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Bhaskar Gurram<a href="https://orcid.org/0000-0003-3169-2225" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3169-2225</div>,&nbsp;</span><span class=""><a href="mailto:Ashish.patel@utsouthwestern.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ashish S. Patel</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Bhaskar Gurram<a href="http://orcid.org/0000-0003-3169-2225" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3169-2225</div>,&nbsp;</span><span class=""><a href="mailto:Ashish.patel@utsouthwestern.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ashish S. Patel</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 13 Dec 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19609.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA<br/> <p> <div class=margin-bottom> Bhaskar Gurram <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ashish S. Patel <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61224-57537></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61223-57538></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. By reviewing epidemiology, pathophysiology, and goals of treatment, we hope to frame the discussion of current and novel therapeutics for the pediatric gastroenterologist. As scientific discovery continues to push the envelope in defining our understanding of pediatric inflammatory bowel disease, the current era of therapeutics gives us hope that a cure may be realized soon. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> pediatric inflammatory bowel disease, Crohn’s disease, ulcerative colitis </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Ashish S. Patel (<a href="mailto:Ashish.patel@utsouthwestern.edu">Ashish.patel@utsouthwestern.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Ashish S. Patel </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Gurram B and Patel AS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Gurram B and Patel AS. Recent advances in understanding and managing pediatric inflammatory bowel disease [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2097 (<a href="https://doi.org/10.12688/f1000research.19609.1" target=_blank>https://doi.org/10.12688/f1000research.19609.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 13 Dec 2019, <b>8</b>(F1000 Faculty Rev):2097 (<a href="https://doi.org/10.12688/f1000research.19609.1" target=_blank>https://doi.org/10.12688/f1000research.19609.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 13 Dec 2019, <b>8</b>(F1000 Faculty Rev):2097 (<a href="https://doi.org/10.12688/f1000research.19609.1" target=_blank>https://doi.org/10.12688/f1000research.19609.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e142>Introduction</h2><p class="" id=d18144e145>The landscape of pediatric inflammatory bowel disease (IBD) is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Additionally, pediatrics is leading the way in several key areas including the understanding of IBD as a monogenic disease in early onset (less than 10) and very early onset (less than 6) cases and around diet as primary therapy utilizing regimens including the specific carbohydrate diet (SCD) and exclusive enteral nutrition (EEN). Just a short 10 years ago, primary therapy in pediatric IBD centered around steroids and oral immunomodulators. With the advent of the first anti-tumor necrosis factor alpha (TNF-α) inhibitor, we were ushered into the biologic era. Anti-TNF agents were more efficacious drugs with the potential for sustained remission. Pediatric gastroenterologists began discussing the potential for an effective therapy like an anti-TNF to change the natural history of this previously aggressive and progressive disease. Though anti-TNFs were the main drug to occupy this class for almost a decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy.</p><p class="" id=d18144e148>As we continue to increase our understanding of therapeutics, the natural evolution of thought shifts from merely modulating the body’s inflammatory response to actually curing the disease. Most current Venn diagrams of pediatric IBD pathophysiology intersect genetic susceptibility, environmental triggers, host immune response, and the gut microbiome resulting in IBD. A key driver, particularly in pediatrics, is the concept that in young children this may be more of a monogenic than a multifactorial disease, as described above. Work by investigators like Dr. Scott Snapper and consortiums like the InterNational Early Onset Paediatric IBD Cohort Study (NEOPICS) has identified unique monogenic immune defects previously classified under the IBD nomenclature that are actually unique defects that have an IBD-like presentation and represent monogenic defects that mimic IBD. These diseases respond and can be cured by treatments like bone marrow transplantation rather than the traditional immunosuppression used in IBD.</p><p class="" id=d18144e151>The understanding of pediatric IBD has also been greatly influenced by the development of the Improve Care Now (ICN) network, led by Dr. Richard Colletti. The network began with 12 centers in 2007, named the Trailblazer Consortium, and has evolved to 107 centers worldwide all pushing the envelope of quality care, resulting in standardized evaluation, consistent therapeutic dosing, focus on nutrition and growth, and, in the end, sustained steroid-free remission. The ICN network has developed clinical pathways, which we will highlight in the appropriate areas, in addition to consistently contributing to the pediatric literature on optimal IBD care.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e157>Epidemiology</h2><p class="" id=d18144e160>The incidence and prevalence of Crohn’s disease (CD) and ulcerative colitis (UC) varies widely across the globe, and there is a paucity of data from many developing countries. Overall, it appears that the rates of pediatric IBD are increasing globally in both developed and developing countries; however, accurate estimates are lacking<sup><a href="#ref-1">1</a></sup>. Based on the reports, there appear to be variations within a country based on geographic location. For example, in the USA, the incidence in Texas was lower compared to the incidence in Wisconsin (2.4 versus 9.5 per 100,000 population, respectively)<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. Population-based health administrative data from Canada showed an incidence of pediatric IBD to be 9.68 per 100,000 population, which means Canada has one of the highest incidences of pediatric IBD in the world<sup><a href="#ref-4">4</a></sup>. In addition, this study did not find a change in the overall incidence for the duration of study between 1999 and 2010. However, there was an increase in incidence in children between 0 and 5 years of age.</p><p class="" id=d18144e178>Racial and geographic differences in the incidence have been well described. In British Columbia, South Asians had a threefold higher incidence of pediatric IBD than non-South Asians, and they had a distinct phenotype with more extensive colonic disease and severe disease compared to the non-South Asian population<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Asian and Hispanic children develop UC more often than CD<sup><a href="#ref-7">7</a></sup>. A higher prevalence with increasing latitudes has been noted for pediatric-onset CD in Scotland<sup><a href="#ref-8">8</a></sup> and for UC in Finland<sup><a href="#ref-9">9</a></sup>. In a population-based study in Europe, the combined incidence rates for CD and UC in all western European centers were twice as high as the rates in the Eastern European centers, implicating a geographic variation in IBD incidence<sup><a href="#ref-10">10</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e207>Advances in the understanding of pediatric IBD pathophysiology</h2><p class="" id=d18144e210>IBD is thought to be of multifactorial origin with complex interaction between genes and environment. Twin studies and family studies have suggested a strong genetic component to IBD pathogenesis and incidence<sup><a href="#ref-11">11</a></sup>. Although having a first-degree relative with IBD confers a greater risk (risk of CD to first-degree relatives of CD patients was 10-fold greater and the risk of UC to relatives of UC patients was eightfold greater than the risk of CD or UC to first-degree relatives of healthy controls) than any known environmental factor, the rate at which the incidence has increased worldwide over the past century<sup><a href="#ref-12">12</a></sup> and more recently in Asia<sup><a href="#ref-13">13</a></sup> significantly exceeds that which can be explained by a genetic drift alone. Genome-wide association studies have identified over 200 genetic loci associated with IBD<sup><a href="#ref-14">14</a></sup>. These genes are implicated in immune homeostasis and the regulation of innate functions like response to microbiota, autophagy, endoplasmic reticulum stress response, and mucosal barrier integrity. These loci are also implicated in adaptive immune function<sup><a href="#ref-15">15</a></sup>, yet combined these explain only 15 to 26% of heritability for IBD. Moreover, these genetic variations are population specific, and more than 70% of these genetic loci are shared with other autoimmune diseases like type 2 diabetes and rheumatoid arthritis.</p><p class="" id=d18144e233>The gut microbiome is thought to play a significant role in the pathogenesis of IBD. Studies have shown alterations in the microbiome in IBD patients compared to healthy controls with decreases in diversity and abundance. However, there are significant inconsistencies regarding the results, potentially from how the microbiome studies were conducted and interpreted. It remains unclear whether microbiome changes lead to intestinal inflammation or change as a result of it.</p><p class="" id=d18144e236>The true interaction between genes and the environment is very difficult to discern and likely involves a complex multidirectional interplay mediated by the epigenome, microbiota, and the innate and acquired immune system.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e242>Goals of treatment</h2><p class="" id=d18144e245>IBD, especially CD, is an aggressive and progressive illness that can lead to irreversible bowel damage. With the introduction of biologics, the approach to the management of IBD has changed from controlling symptoms which do not necessarily correlate with inflammation to achieving mucosal healing a more objective measure. Thus, over the past two decades, there has been a shift in the treatment goal from relief of symptoms to inducing mucosal healing while continuing to maintain growth, support nutrition, improve quality of life, and minimize side effects. Preliminary support for this paradigm shift came from the first large trial of infliximab (IFX), ACCENT-I. Patients who achieved mucosal healing were less likely to have CD-related hospitalizations and surgery<sup><a href="#ref-16">16</a></sup>. Furthermore, using mucosal healing as an end point for decision making was found to be more cost-effective than a strategy based on clinical symptoms by decreasing disease-related complications<sup><a href="#ref-17">17</a></sup>.</p><p class="" id=d18144e256>There are several other markers in the management of IBD. These include CRP, albumin, fecal calprotectin, and antibodies against various antimicrobial antigens<sup><a href="#ref-18">18</a></sup>. Although elevated CRP correlates well with both endoscopic and histologic evidence of inflammation, in patients with isolated small bowel CD and those with UC the correlation with disease activity is poor<sup><a href="#ref-19">19</a></sup>. Similarly, although calprotectin is considered a good marker of intestinal inflammation, especially in UC, it does not correlate well with CD activity, especially small bowel CD<sup><a href="#ref-18">18</a></sup>.</p><p class="" id=d18144e271>There are several reports discussing the role of serological markers in IBD management. One study involving a large pediatric multicenter cohort demonstrated that disease progression from uncomplicated to internal penetrating or stricturing disease phenotypes and CD-related surgery is accelerated in the presence of antimicrobial immune reactivity that included anti-Cbir1 (flagellin), anti-outer membrane protein C antibody (anti-ompC), anti-<i>Saccharomyces cerevisiae</i> antibody (ASCA), and perinuclear anti-neutrophil cytoplasmic antibody (pANCA). Both the number of immune responses and the magnitude of immune response to various microbial antigens were predictive of aggressive disease phenotypes. The group positive for all three antibodies and those patients with the highest magnitude of response (the highest quartile sum group 4) exhibited the most rapid disease progression<sup><a href="#ref-20">20</a></sup>. The odds ratio (OR) for the development of internal penetrating disease was 5.0 and 9.5 for children with reactivity to two and three antigens, respectively. Another cross-sectional study involving an adult population demonstrated that patients who were positive for ASCA IgA and IgG were 8.5 times and 5.5 times more likely to undergo early (&lt;3 years) surgery than patients negative for ASCA IgA and IgG<sup><a href="#ref-21">21</a></sup>.</p><p class="" id=d18144e285>Several studies have suggested that nucleotide-binding oligomerization domain 2 (<i>NOD2</i>) mutations are associated with an increased risk of complicated CD. The <i>NOD2</i> gene codes for NOD 2 protein, which is an intracellular pattern recognition receptor primarily involved in recognizing muramyl dipeptide, a molecule present on certain bacteria, and helps in modulating the immune system. In a meta-analysis, Adler <i>et al.</i> reported that the presence of a single <i>NOD2</i> mutation predicted an 8% increase in the risk for complicated disease (B2 or B3) and a 41% increase with two mutations<sup><a href="#ref-22">22</a></sup>. Although the predictive power associated with a single <i>NOD2</i> mutation for complicated disease was weak (relative risk: 17%), the presence of two <i>NOD2</i> mutations had 98% specificity for predicting complicated disease<sup><a href="#ref-22">22</a></sup>. However, <i>NOD2</i> mutations were poor predictors for postoperative recurrence of CD<sup><a href="#ref-23">23</a></sup>.</p><p class="" id=d18144e323>Kugathasan <i>et al.</i> derived a risk stratification model for complicated disease behavior based on clinical, serological, gene expression pattern, and microbiota data on 913 treatment-naïve pediatric CD patients<sup><a href="#ref-24">24</a></sup>. These patients were prospectively followed for about 36 months and it was found that about 9% (78) of patients had complicated disease course. This risk stratification model had an area under the receiver operator characteristic curve of 0.72, sensitivity of 69%, specificity of 71%, positive predictive value of 24%, and negative predictive value of 94%. Older age at diagnosis, African American race, and ASCA and CBir1 sero-positivity were associated with disease complications; early anti-TNF-α therapy was associated with a reduction in penetrating disease, and an ileal extracellular matrix gene signature at diagnosis was associated with stricturing disease.</p><p class="" id=d18144e333>Serological markers (ASCA, pANCA, anti-cbir1, anti-flagellin, etc.) and genetic markers are rarely used in clinical practice, as their applicability is limited by their limited sensitivity and the added cost.</p><p class="" id=d18144e336>Seigel <i>et al.</i> developed and validated a tool (Personalized Risk and Outcome Prediction Tool [PROSPECT]) to predict an individual patient’s risk of developing a CD complication based on clinical, serologic, and genetic variables<sup><a href="#ref-25">25</a></sup>. The PROSPECT tool generates an individualized risk based on the information provided and groups the patients into low, medium, and high risk for surgery in 3 years and could help physicians and patients on personalized treatment options.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e349>Exclusive enteral nutrition</h2><p class="" id=d18144e352>EEN has been used for several decades in the induction of remission in patients with CD. It is more widely prescribed in Canada and the European nations than in the US. EEN involves supplying 100% of one’s caloric needs as a formula, polymeric or hydrolyzed, enterally for 8–12 weeks. The remission rates in most cohort studies range from 60 to 80%<sup><a href="#ref-26">26</a>–<a href="#ref-28">28</a></sup>, which is equivalent to corticosteroid remission rates. When compared to corticosteroids, which are also used for the induction of remission, EEN is as effective at decreasing symptoms and biochemical markers of inflammation (ESR and CRP) but, unlike steroids, it also leads to decreased endoscopic severity grossly and histologically<sup><a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup>. When compared to corticosteroids, EEN is also associated with improved linear growth, bone mineralization, and lean body mass acquisition as opposed to fat mass acquisition with corticosteroids; additionally, it is not immunosuppressive<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>. Therefore, EEN can be particularly helpful in patients with significant growth failure or malnutrition.</p><p class="" id=d18144e376>European and North American guidelines recommend EEN as the first-line agent in active luminal CD diagnosed under 17 years of age<sup><a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. Although early data indicated that EEN was more likely effective in patients with small bowel involvement<sup><a href="#ref-34">34</a></sup>, subsequent data have shown effectiveness regardless of the site of involvement<sup><a href="#ref-27">27</a></sup>. However, efficacy has not been demonstrated in perianal, fistulizing, or stricturing CD.</p><p class="" id=d18144e394>In a recent meta-analysis, Swaminathan <i>et al.</i> demonstrated that EEN is equally efficacious in inducing remission in newly diagnosed (OR = 1.61 [95% CI 0.87, 2.98]) and relapsed (OR = 0.76 [95% CI 0.29–1.98]) patients<sup><a href="#ref-35">35</a></sup>. In this study, the likelihood of achieving mucosal healing was higher with EEN compared to steroids. Biomarker normalization did not differ.</p><p class="" id=d18144e404>The exact mechanism of action has remained uncertain, but various mechanisms have been proposed, including decreased antigen exposure, alteration of the resident microbiome<sup><a href="#ref-36">36</a></sup>, restoration of epithelial barrier integrity, and decreased immune system activation<sup><a href="#ref-37">37</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e419>Specific carbohydrate diet and other diet-based therapies</h2><p class="" id=d18144e422>The SCD was first developed in the 1920’s by Dr. Sydney Haas as a therapy for celiac disease and later popularized by a mother of one of Dr. Haas’ patients, Elaine Gottschall, a biochemist who wrote the book <i>Breaking the Vicious Cycle: Intestinal Health Through Diet.</i> The diet is a nutritionally balanced one that removes grains, dairy, processed foods, and sugars, except for honey. The theory is that these items pass undigested or poorly digested into the distal intestine, allowing the overgrowth of harmful bacteria. This has been re-energized recently by the work of Dr. David Suskind at Seattle Children’s who has published several small case series showing the efficacy of the SCD in treating pediatric IBD<sup><a href="#ref-38">38</a>–<a href="#ref-41">41</a></sup>. The diet is being evaluated nationally in a trial called PRODUCE led by the ICN network centers.</p><p class="" id=d18144e435>The CD exclusion diet (CDED) is an exclusion diet supplemented with partial enteral nutrition. This involves eliminating certain foods that are deemed to induce dysbiosis, specifically gluten, dairy products, gluten-free baked goods and breads, animal fat, processed meats, products containing emulsifiers, canned goods, and all packaged products with an expiration date. CDED has been studied and found to be beneficial in both children and adults with IBD. In a recent randomized study that included 78 pediatric patients with mild-to-moderate CD, CDED was found to be better tolerated and had higher rates of remission compared to EEN<sup><a href="#ref-42">42</a></sup>. Other less-well-studied diets in IBD include ordinary food-based diets that replicate EEN (CD-TREAT)<sup><a href="#ref-43">43</a></sup>, the food influence on Intestinal MicrobioTa diet<sup><a href="#ref-44">44</a></sup>, the anti-inflammatory diet<sup><a href="#ref-45">45</a></sup>, and low-fermentable oligosaccharide, disaccharide, monosaccharide, and polyols (low FODMAP) diet<sup><a href="#ref-46">46</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e461>5-aminosalicylic acid (5ASA) compounds</h2><p class="" id=d18144e464>5-ASA compounds are one of the earliest compounds introduced for the management of IBD. Sulfasalazine was the only 5-ASA formulation shown to have modest benefit compared to placebo in mild-to-moderate CD restricted to the colon<sup><a href="#ref-47">47</a></sup>. They are not found to be of any benefit in small bowel CD or in moderate-to-severe CD and should not be used<sup><a href="#ref-48">48</a>–<a href="#ref-50">50</a></sup> in these patients. ECCO and ESPGHAN guidelines recommend 5-ASA compounds as first-line agents for the induction and maintenance of mild-to-moderate UC<sup><a href="#ref-51">51</a></sup>. Combination of oral and rectal 5-ASA therapy is considered superior to 5-ASA monotherapy<sup><a href="#ref-52">52</a></sup>. The ICN Model IBD Care document recommends oral dosing of 60 to 100 mg/kg/day in active disease and 30 to 100 mg/kg/day in maintenance phase. In a randomized controlled study of mesalamine, there was no difference in the efficacy of once versus twice daily dosing for mild-to-moderate pediatric UC<sup><a href="#ref-53">53</a></sup>; thus, once-daily dosing is encouraged to improve patient compliance. The overall efficacy as measured by steroid-free remission at 1 year with mesalamine ranges from 32 to 45%<sup><a href="#ref-51">51</a></sup>. Sulfasalazine was found to be superior to other 5-ASA medications but also had increased side effects<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. It is estimated that up to 20 to 25% of patients discontinue sulfasalazine because of side effects. The most common side effects encountered with sulfasalazine include nausea, headache, fever, and rash. Curcumin (an active component of turmeric) 3 g/day with mesalamine was found to be more effective than mesalamine alone in achieving clinical and endoscopic remission in patients with mild-to-moderate UC without an increase in adverse effects<sup><a href="#ref-56">56</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e509>Thiopurines</h2><p class="" id=d18144e512>Azathioprine (AZA) and 6-mercaptopurine (6-MP) have traditionally been the first-line immunomodulators used for the maintenance of remission in CD and UC. However, data concerning long-term risks with thiopurines including skin cancer, lymphoma, and hepatosplenic T-cell lymphoma, particularly in young males receiving thiopurines alone or in combination with anti-TNF-α antibodies, have led pediatric gastroenterologists to favor methotrexate (MTX) in children with CD. Results from the multicenter pediatric IBD network (PIBDNet) showed that 69% of patients (45 of 65 patients) achieved remission within 180 days of thiopurine initiation. However, only 47% and 23% remained in sustained steroid-free remission at 6 and 12 months, respectively. There was significant variation in the dose of thiopurine used, and there was variation in serum 6-TG levels<sup><a href="#ref-57">57</a></sup>.</p><p class="" id=d18144e519>AZA is a prodrug and is converted non-enzymatically to 6-MP. Although AZA and 6-MP could be used interchangeably, the dosing is different. The recommended dose for AZA is 1.5 to 2.5 mg/kg per day orally (maximum dose 200 mg per day), and 6-MP is generally given at doses of between 1 and 1.5 mg/kg per day orally (maximum 150 mg per day). To determine a safe starting dose, thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity) testing is recommended prior to beginning treatment with 6-MP or AZA. TPMT is an enzyme that is essential in the metabolism of thiopurines. Approximately 90% of patients are homozygous for the allele TPMT 1 (TPMT 1/1 genotype) and have normal or rapid metabolism of thiopurines. In contrast, 10% of patients have reduced TPMT activity (TPMT 1/3a genotype) and metabolize thiopurines more slowly. These patients typically respond to much lower doses of the medication (0.5 mg/kg/day of 6-MP). Approximately 1 in 300 patients has absent TPMT activity (TPMT 3a/3a genotype), does not metabolize the medication, and can develop agranulocytosis<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>.</p><p class="" id=d18144e529>However, in a systematic review, thiopurine metabolite testing did not safely predict clinical outcome but may facilitate toxicity surveillance and treatment optimization in poor responders<sup><a href="#ref-60">60</a></sup>. Current evidence favors the combination of thiopurine metabolites, WBC and aminotransferase monitoring for prompt identification of hematologic and hepatic toxicity, safe dose adjustment, and treatment modification in cases of suboptimal clinical outcome or non-compliance<sup><a href="#ref-60">60</a>–<a href="#ref-62">62</a></sup>. All patients should have regular clinic follow-up with documented lymph node exam and abdominal palpation for hepatic or splenic enlargement.</p><p class="" id=d18144e543>Although thiopurines may be effective in prolonging response and remission<sup><a href="#ref-63">63</a></sup>, adverse side effects may reduce their utilization. In one series that looked at 95 children and adolescents with IBD who received AZA or 6-MP, 54% had no adverse effect, 28% experienced side effects necessitating dose reduction (elevated liver transaminases, leukopenia, and lymphopenia), and 18% required drug discontinuation because of pancreatitis, recurrent fever, nausea and/or vomiting, and recurrent infections such as sinusitis<sup><a href="#ref-64">64</a></sup>.</p><p class="" id=d18144e555>A newer formulation of 6-MP is being developed that is locally active and is a delayed-release formulation with minimal systemic absorption. In a phase II study, Israeli <i>et al.</i> reported that in CD when compared to systemically delivered 6-MP (Purinethol), delayed-release 6-MP (DR-6MP) showed similar efficacy, a greater proportion of remission with low systemic bioavailability, and a low incidence of side effects<sup><a href="#ref-65">65</a></sup>.</p><p class="" id=d18144e565>Owing to the published risk of hemophagocytic lymphohistiocytosis (HLH) with primary EBV while on thiopurines, there is a growing practice of screening all newly diagnosed children for EBV status and, if naïve, avoiding all thiopurine use.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e571>Methotrexate</h2><p class="" id=d18144e574>MTX is an anti-folate agent that is used for induction and maintenance of remission in CD<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. It is not useful in the management of UC<sup><a href="#ref-68">68</a>–<a href="#ref-70">70</a></sup>. Most of the evidence for efficacy in pediatric patients comes from several retrospective pediatric series, a recent systematic review<sup><a href="#ref-71">71</a></sup>, and extrapolated information from one randomized placebo-controlled trial in adults with CD<sup><a href="#ref-72">72</a></sup>. The pooled achieved clinical remission rate for pediatric CD patients on monotherapy within 3–6 months was 57.7% (95% CI 48.2–66.6%) (<i>P</i> = 0.22; I<sup>2</sup> = 29.8%). The clinical remission was 37.1% (95% CI 29.5–45.5%) (<i>P</i> = 0.20; I<sup>2</sup> = 37.4%) for maintenance therapy at 12 months<sup><a href="#ref-71">71</a></sup>. In general, MTX given orally has significant variability in bioavailability among individuals; subcutaneous injection is the preferred formulation<sup><a href="#ref-73">73</a></sup>. The superiority of subcutaneous MTX compared to oral MTX is well demonstrated in rheumatology literature<sup><a href="#ref-73">73</a></sup>.</p><p class="" id=d18144e624>MTX has dose-limiting side effects including hepatotoxicity and bone marrow suppression. In one systematic review that included 12 high-quality studies evaluating hepatotoxicity (defined as elevated liver transaminases) when used in a pediatric IBD population, Valentino <i>et al.</i> described hepatotoxicity in 1 in 10 patients, 1 in 15 patients needed dose reduction, and 1 in 22 patients needed discontinuation of MTX. Based on these findings, the authors recommended monitoring liver biochemistries at baseline, every 2 weeks for the first month, and then every 2–3 months<sup><a href="#ref-74">74</a></sup>. Although there is insufficient literature looking at the utility of folate supplementation with MTX in the IBD population, it is known to be beneficial in patients with rheumatoid arthritis. In rheumatoid arthritis, folate supplementation (1 mg/day) with MTX is known to reduce the risk of side effects including liver transaminase elevation and gastrointestinal side effects like nausea and vomiting<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. Folate supplementation also promoted compliance and reduced patient withdrawal compared to placebo<sup><a href="#ref-76">76</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e648>Anti-TNFs</h2><p class="" id=d18144e651>IFX, a chimeric monoclonal antibody against TNF-α, is the most commonly used biologic in the treatment of children with CD and UC. Standard IFX dosing in children is 5 mg/kg at 0, 2, and 6 weeks during induction followed by maintenance doses of 5 mg/kg every 8 weeks.</p><p class="" id=d18144e654>The REACH trial<sup><a href="#ref-77">77</a></sup> is a landmark study showing the efficacy of IFX in children for induction and maintenance of remission in moderate-to-severe CD. In this study of 112 children with CD, approximately 60% of patients had clinical response or remission at 1 year. Subsequent studies have shown that up to 50% of patients would need dose modification by 54 weeks to retain or regain efficacy<sup><a href="#ref-78">78</a>–<a href="#ref-80">80</a></sup>. Following maintenance therapy initiation, the likelihood of continuing maintenance IFX at 1, 2, and 3 years was 93%, 78%, and 67%, respectively<sup><a href="#ref-80">80</a></sup>.</p><p class="" id=d18144e672>In moderate-to-severe active pediatric UC that failed conventional therapy (5-ASAs, corticosteroids, or immunomodulators), IFX was found to be safe and effective, inducing a response at week 8 in 73.3%<sup><a href="#ref-81">81</a></sup>. However, the overall remission rate at week 54 for all enrolled patients was 28.6%<sup><a href="#ref-81">81</a></sup>.</p><p class="" id=d18144e683>Current evidence indicates that the treatment failure may result in part from low IFX serum levels. IFX trough levels of &lt;3 mg/ml are associated with worse clinical outcomes, and dose optimization based on trough levels has proven beneficial in some studies<sup><a href="#ref-78">78</a>,<a href="#ref-82">82</a>,<a href="#ref-83">83</a></sup>. Factors contributing to the observed pharmacokinetic differences include BMI and sex, inflammatory burden (extent and severity of disease), serum albumin, and presence or absence of a concomitant immunomodulator and of anti-drug antibodies (neutralizing antibodies)<sup><a href="#ref-84">84</a></sup>. Among these factors, weight and serum albumin levels have been found to have the largest influence<sup><a href="#ref-84">84</a></sup>. In one pediatric study looking at the correlation of serum IFX levels at week 14 as predictors of remission at week 54, the authors found that trough levels of at least 3 mg/ml were associated with a positive predictive value of only 76% for persistent clinical remission at week 54<sup><a href="#ref-78">78</a></sup>. Increasing the trough threshold to at least 7 mg/ml improved the positive predictive value of persistent remission at week 54 to 100%<sup><a href="#ref-78">78</a></sup>.</p><p class="" id=d18144e713>Using the data from 112 patients with CD in the REACH trial, Frymoyer <i>et al.</i> constructed a Monte Carlo simulation analysis of hypothetical children with CD to address dose optimization of IFX based on weight and albumin levels. They found that standard IFX maintenance dosing of 5 mg/kg every 8 weeks is predicted to frequently result in trough concentrations of &lt;3 mg/ml in children with CD with an albumin of 4 g/dl or less<sup><a href="#ref-85">85</a></sup>. They estimated that only 21% or 41% of children would achieve trough concentrations of &gt;3 mg/ml if albumin levels were 3 g/dl or 4 g/dl, respectively, and thus a substantial proportion of patients would need an increase in dose and frequency to maintain adequate drug exposure at week 14<sup><a href="#ref-85">85</a></sup>.</p><p class="" id=d18144e727>Thus, early IFX trough levels could help in guiding dose optimization and likely improve clinical outcomes. Although therapeutic drug monitoring (TDM), defined as the evaluation of levels of drug and anti-drug antibodies, has proven to be effective in optimizing anti-TNF therapy in maintenance phase of IBD, the studies are limited to monitoring levels in induction phase. However, logically thinking, it is likely that there is a beneficial effect of monitoring levels during induction phase and optimizing them rather than waiting until the maintenance phase. Based on preliminary data in adults with UC, week 2 and week 6 trough levels of 30 to 36 and 24 to 30 mg/ml at week 2 and 6, respectively, were associated with early mucosal healing<sup><a href="#ref-86">86</a></sup>. In children with moderate-to-severe UC, week 8 levels of serum IFX concentrations (≥41.1 μg/ml) were associated with greater proportions of patients achieving efficacy endpoints (clinical response: 92.9%; mucosal healing: 92.9%; and clinical remission: 64.3%) versus those with lower serum concentrations (&lt;18.1 μg/ml; 53.9%, 53.9%, and 30.8%, respectively)<sup><a href="#ref-87">87</a></sup>. A retrospective study from a tertiary care center demonstrated that interval shortening rather than dose escalation results in higher IFX levels, and the authors recommended a dose of every 6 weeks for optimizing levels<sup><a href="#ref-88">88</a></sup>.</p><p class="" id=d18144e742>Based on the above data, we recommend checking IFX trough levels before the fourth dose (week 14 dosing) in CD to guide subsequent intervals between dosing and achieve target levels of &gt;5 mg/ml. For IFX in severe UC, our practice has been to start with 10 mg/kg, in particular in patients with documented hypoalbuminemia. For UC, we recommend checking levels before the third (week 6 dosing) induction dose with levels of &gt;20 mg/ml and adjusting the subsequent doses accordingly.</p><p class="" id=d18144e745>Adalimumab, a human IgG monoclonal antibody against TNF-α, was approved for use in children with CD in 2012. The standard recommended dosing in children weighing &gt;40 kg is 160 mg and 80 mg for induction 2 weeks apart and 40 mg every 2 weeks for maintenance. For children weighing &lt;40 kg, induction dosing is 80 mg and 40 mg 2 weeks apart and 20 mg every 2 weeks for maintenance. In the pivotal study IMAgINE 1, using adalimumab in moderate-to-severe CD, 33.3% of patients remained in remission at week 54. Patients who were naïve to IFX had higher remission rates (45% versus 19%)<sup><a href="#ref-89">89</a></sup>. About 50% of patients in the IMAgINE 1 trial needed dose escalation to weekly dosing from every other week dosing based on clinical symptoms; this frequent dosing was well tolerated<sup><a href="#ref-90">90</a></sup>. The IMAgINE 2 study assessed the long-term efficacy through week 240 of adalimumab<sup><a href="#ref-91">91</a></sup>. At week 240, about 41% and 48% of those enrolled achieved remission and response as assessed by PCDAI&lt;10 and PCDAI decrease by &gt;15 points from baseline, respectively<sup><a href="#ref-91">91</a></sup>. In a systematic review that included 14 studies (one randomized controlled trial and 13 case series) and 664 patients, the pooled remission rates were 44% (n = 169/383) at 12 months. Of the total patients, 6% (n = 13/207) were classified as primary non-responders and 12% (n = 69/599) had severe adverse events reported, including two deaths and one medulloblastoma<sup><a href="#ref-92">92</a></sup>.</p><p class="" id=d18144e768>Based on a network meta-analysis of five randomized controlled trials in moderate-to-severe adult UC, adalimumab was comparable in efficacy to IFX at 52 weeks of maintenance treatment<sup><a href="#ref-93">93</a></sup>. Based on the retrospective studies, adalimumab in pediatric UC showed similar results to those of adults with UC<sup><a href="#ref-94">94</a></sup>. While on adalimumab, reactive TDM is recommended in adults, with a recommended minimum drug concentration at week 4 of &gt;7 mg/ml to achieve mucosal healing and levels of &gt;5 mg/ml during maintenance phase<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>.</p><p class="" id=d18144e786>Golimumab, another human IgG monoclonal antibody against TNF-α, is approved for use in adults with UC. In an open-label pharmacokinetic study of 35 children with moderate-to-severe UC, golimumab showed a week 6 clinical response in 60%, with mucosal healing achieved in 23%, and clinical remission in 57% at week 14<sup><a href="#ref-96">96</a>,<a href="#ref-97">97</a></sup>. The recommended dosing in children with UC for induction is 200 mg at week 0 and 100 mg at week 2 if body weight is &gt;45 kg and 120 mg/m<sup>2</sup> at week 0 and 60 mg/m<sup>2</sup> at week 2 if body weight is &lt;45 kg. Maintenance dosing is 100 mg every 4 weeks for &gt;45 kg body weight and 60 mg/m<sup>2</sup> every 4 weeks if body weight is &lt;45 kg<sup><a href="#ref-96">96</a>,<a href="#ref-97">97</a></sup>. In adults, the expected minimum concentration at week 6 for golimumab should be &gt;2.5 mg/ml, and maintenance trough levels should be &gt;1 mg/ml<sup><a href="#ref-95">95</a></sup>.</p><p class="" id=d18144e818>Safety issues of TNF-α medications include acute infusion reactions (within 4 hours of IFX infusion), delayed hypersensitivity reactions (beyond 4 hours and up to 14 days), and serious and opportunistic infections. In one retrospective study that included a total TNF-α exposure of 390.5 patient-years (PYs), the overall incidence rate of serious adverse events (SAEs) for IFX was 22.49/100 PYs<sup><a href="#ref-98">98</a></sup>. The most common SAEs were anaphylactoid reactions (n = 18) followed by infectious events (n = 9) and TNF-α antagonist-induced lupus-like syndrome (n = 3). The overall incidence rate of SAEs for adalimumab was 4.71/100 PYs (two infectious SAEs). No malignancies or deaths were observed in this cohort. When used as monotherapy TNF-α medications are not associated with increased risk of malignancy or HLH in the pediatric population<sup><a href="#ref-99">99</a></sup>. However, in the adult population, there is increased risk of malignancies even with monotherapy, with the highest risk associated with combination therapy with thiopurines<sup><a href="#ref-100">100</a></sup>. Psoriasis has been well documented as an adverse class effect of TNF-α, but it is usually mild and controllable in most patients with topical therapy<sup><a href="#ref-101">101</a></sup>.</p><p class="" id=d18144e837>There is no clear evidence that pre-medication with IFX prevents the development of acute infusion reaction<sup><a href="#ref-102">102</a></sup>, and we do not routinely use or recommend the use of pre-medications prior to IFX infusion. Recommended infection screening before starting TNF-α medications includes screening for tuberculosis (PPD, quantiferon TB, or chest X-ray), hepatitis B (Hep B surface antigen and antibody), and varicella immunization status (confirmed vaccination, exposure, or checking for varicella IgG)<sup><a href="#ref-51">51</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e851>Combination therapy</h2><p class="" id=d18144e854>The use of an immunomodulator drug, either thiopurine (AZA or 6-MP) or MTX, with TNF-α antibody is termed combination therapy. Demonstrated benefits of combination therapy include a reduction in the formation of antibodies to TNF-α and increased durability of biologic response<sup><a href="#ref-103">103</a></sup>. However, the benefits on clinical remission and mucosal healing are unclear. Some of the risks to consider in using combination therapy are increased risk of infections and increased risk of malignancy.</p><p class="" id=d18144e861>The SONIC trial comparing the efficacy of AZA, IFX, and AZA+IFX that included 508 patients with CD naïve to AZA and IFX showed higher steroid-free remission and mucosal healing with combination of AZA and IFX<sup><a href="#ref-104">104</a></sup>. Combination therapy with AZA appears to improve efficacy by increasing the pharmacokinetic features of IFX<sup><a href="#ref-105">105</a></sup>. Based on these data, the American Gastroenterological Association (AGA) recommended using combination therapy for induction of remission in adults with CD<sup><a href="#ref-106">106</a></sup>.</p><p class="" id=d18144e876>Data on combination therapy in pediatric CD comes from one randomized controlled trial and several retrospective studies and the results are inconclusive, with some studies showing no benefit of combination therapy<sup><a href="#ref-107">107</a>–<a href="#ref-111">111</a></sup> and others showing benefit with regard to remission and durability of response to combination therapy<sup><a href="#ref-112">112</a>–<a href="#ref-116">116</a></sup>. One therapeutic option is to use low-dose immunomodulators in combination with TNF-α antibodies<sup><a href="#ref-113">113</a>,<a href="#ref-117">117</a></sup>.</p><p class="" id=d18144e900>Two important safety concerns with the use of combination therapy are increased risk of infections and malignancy. Two of the important risk factors for increased risk of infection in IBD patients were identified to be moderate-to-severe disease and concomitant steroid use. A clinical report on combination therapy by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) concluded that based on the adult literature, the use of combination therapy may have a net effect of reducing infectious risk in select patients by improving disease remission rates and minimizing steroid use<sup><a href="#ref-118">118</a></sup>.</p><p class="" id=d18144e908>With regard to malignancy risk, especially with lymphoma, the risk is primarily attributed to thiopurines and there may be a slight increased risk when anti-TNFs are used in combination<sup><a href="#ref-99">99</a>,<a href="#ref-119">119</a></sup>. One exception is hepatosplenic T cell lymphoma (HSTCL). An increased incidence of HSTCL has been reported in young male patients treated with either thiopurines as monotherapy or in combination with a TNF-α<sup><a href="#ref-120">120</a>,<a href="#ref-121">121</a></sup>.</p><p class="" id=d18144e925>Taking the above benefits and risks into consideration, there certainly is a group of patients who benefit from using combination therapy to induce remission and prevent long-term risks associated with CD while at the same time minimizing the side effects of combination therapy. At our center, we typically use combination therapy in patients with moderate-to-severe CD, especially with stricturing or fistulizing disease and severe perianal disease. We prefer to use MTX over thiopurines in males and those with no evidence of EBV infection in the past. We also use lower doses of immunomodulators when used in combination with TNF-α drugs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e932>Anti-adhesion agents</h2><p class="" id=d18144e935>Anti-adhesion molecules act by blocking the trafficking of T-lymphocytes from the lymphoid organs and bloodstream to the site of gut inflammation. There are two medications in this group. Natalizumab was the first anti-adhesion agent approved for the management of moderate-to-severe CD. Natalizumab is a monoclonal antibody against the α4 integrin on lymphocytes. Specifically, it blocks the α4β7 and α4β1 integrins on the T cells from binding mucosal addressin cell adhesion molecule-1 (MADCAM-1) and vascular cell adhesion molecule-1 (VCAM-1), respectively<sup><a href="#ref-122">122</a></sup>. Natalizumab, in comparison to placebo, has been reported to be more effective in the induction and maintenance of remission in patients with CD<sup><a href="#ref-123">123</a></sup>. The evidence in pediatrics is limited to two case series<sup><a href="#ref-124">124</a>,<a href="#ref-125">125</a></sup>. Hyams <i>et al.</i> included 31 adolescents with severe CD and reported a response rate of 55% and remission of 29% at 10 weeks<sup><a href="#ref-124">124</a></sup>.</p><p class="" id=d18144e960>Natalizumab’s use has been drastically limited by its association with progressive multifocal leukoencephalopathy (PML), a life-threatening CNS infection caused by the reactivation of John Cunningham virus (JCV). This side effect is thought to be directly related to the blockade of lymphocyte migration to the CNS by natalizumab. The risk factors implicated in PML include the presence of positive anti-JCV antibodies, prior immunosuppressant therapy, and prolonged duration of natalizumab therapy (&gt;2 years). Although natalizumab was withdrawn from the US market in 2005, it was reintroduced in 2008 under restricted usage in patients with none of the risk factors mentioned above<sup><a href="#ref-123">123</a></sup>.</p><p class="" id=d18144e967>The second anti-adhesion biologic is vedolizumab. Vedolizumab is a monoclonal antibody against α4β7 integrin on lymphocytes, blocking their binding to MADCAM-1 and thus migration of the lymphocytes into the gastrointestinal tract mucosa. As opposed to natalizumab, vedolizumab is gut specific and does not lead to systemic immunosuppression and thus the side effects were found to be very similar to those seen with placebo<sup><a href="#ref-126">126</a></sup>. Vedolizumab has been found to be superior to placebo for induction of remission at week 6 for adult-onset CD and UC subjects with moderately to severely active disease<sup><a href="#ref-126">126</a>–<a href="#ref-130">130</a></sup>. In a single-center prospective observational study, Conrad <i>et al.</i><sup><a href="#ref-131">131</a></sup> followed 21 pediatric patients (13 to 21 years) with severe TNF-α-refractory IBD (16 CD, three UC, and two IBD-U). They reported a response rate in 57.9% of patients at 22 weeks with steroid-free remission of 20% at 22 weeks. Hamel <i>et al.</i><sup><a href="#ref-132">132</a></sup>, in a retrospective cohort of 12 TNF-α and corticosteroid-refractory IBD patients (10 UC and two CD), reported that when vedolizumab used in combination with tacrolimus 9 of 12 (75%) patients avoided colectomy or IBD-related surgery at 24 weeks and 8 out of 12 (68%) continued on vedolizumab maintenance with no adverse events up to 80 weeks. A retrospective multicenter study from the pediatric IBD Porto group of ESPGHAN included 64 children with IBD (41 UC/IBD-U and 23 CD) refractory to TNF-α medications and reported a week 14 corticosteroid-free remission of 37% in UC and 14% in CD<sup><a href="#ref-133">133</a></sup>. Similarly, in a retrospective multicenter study from the US involving 52 IBD patients (58% CD and 42% UC), the authors reported a 14 week remission rate of 76% in UC and 42% in CD<sup><a href="#ref-134">134</a></sup>. The dose of vedolizumab used in children is 6 mg/kg with a maximum dose of 300 mg, with induction given at 0, 2, and 6 weeks followed by maintenance every 8 weeks<sup><a href="#ref-134">134</a>,<a href="#ref-135">135</a></sup>. The recently released VARSITY study (Sands <i>et al.</i>, DDW 2019) showed vedolizumab to have superior efficacy versus adalimumab for moderate-to-severe UC. This was a phase IIIb randomized double-blind study of 769 adults with moderately to severely active UC who had failed other therapies. Clinical remission at week 52 was the primary endpoint and was 31% with vedolizumab compared to 22% with adalimumab, and patients treated with vedolizumab had higher mucosal healing rates. Adverse events were similar in the two groups. This is an important study because it is the first comparative effectiveness study in IBD comparing two biologic therapies head to head. As opposed to natalizumab, vedolizumab has an excellent safety profile. The most frequently reported adverse events are minor and include headaches, fever, arthralgias, and nausea<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a>,<a href="#ref-129">129</a>,<a href="#ref-136">136</a></sup>. Infusion reactions are low at 3.5 per 1,000 infusions<sup><a href="#ref-136">136</a>,<a href="#ref-137">137</a></sup>.</p><p class="" id=d18144e1032>Etrolizumab is a humanized monoclonal antibody against the β7 subunit of α4β7 and αEβ7 which prevents their interaction with MADCAM-1 and E-cadherin, respectively, and thus disrupts leukocyte migration into intestinal tissue<sup><a href="#ref-123">123</a></sup>. Etrolizumab has been shown to be well tolerated and effective in a phase II clinical trial of patients with moderate-to-severe UC<sup><a href="#ref-138">138</a></sup>; phase III clinical trials are underway. There are no pediatric studies of Etrolizumab to date.</p><p class="" id=d18144e1044>Other medications in this group include AJM300, an orally active, small molecule with a mechanism of action like natalizumab, and PF-00547659, a monoclonal antibody administered subcutaneously against intestinal epithelial adhesion molecule MADCAM-1<sup><a href="#ref-123">123</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e1054>Interleukin inhibitors</h2><p class="" id=d18144e1057>Interleukin-12 (IL-12) and interleukin-23 (IL-23) are pro-inflammatory cytokines that induce the differentiation of naïve CD4<sup>+</sup> T cells into T-helper 1 and T-helper 17 cells, respectively, and are important in the pathogenesis of IBD. Ustekinumab is a human monoclonal antibody against the p40 subunit that is common to both IL-12 and IL-23, consequently preventing the interaction of these cytokines with their receptors on naïve T cells and preventing further downstream signaling and the pro-inflammatory cascade. It was approved for the treatment of moderate-to-severe CD in adults in 2016.</p><p class="" id=d18144e1063>The adult UNITI-1 and UNITI-2 studies demonstrated clinical response in adults with TNF-α-naïve and TNF-α-exposed moderate-to-severe CD patients. Responders from UNITI-1 and UNITI-2 were enrolled in a subcutaneous ustekinumab maintenance trial (IM-UNITI), which showed a clinical remission at week 44 of 53.1% in the group that received 90 mg every 8 weeks compared to 48.8% in those receiving ustekinumab every 12 weeks and 35.9% in those receiving placebo<sup><a href="#ref-139">139</a></sup>. The rates of adverse events were not statistically different between the treatment and placebo arm in all of these trials. Also, ustekinumab is observed to lead to significant reductions in endoscopic disease activity at week 8 of induction therapy<sup><a href="#ref-140">140</a></sup>.</p><p class="" id=d18144e1074>There is an evolving body of literature for the use of ustekinumab in pediatric patients. This consists of case reports, one case series, and a recently published real-world experience on ustekinumab in pediatric patients. In the case series, the suggested dosing is 6 mg/kg IV infusion for induction followed by 45 mg every 8 weeks for maintenance in children weighing &lt;40 kg and 90 mg every 8 weeks for children weighing &gt;40 kg. In the real-world experience, 52 patients receiving ustekinumab were evaluated and included baseline characteristics and predictors of response. The study concluded that ustekinumab monotherapy is possible and preferable in children. A caveat that we have also noted was the need for dose amplification, 57% in this real-world experience<sup><a href="#ref-141">141</a>–<a href="#ref-143">143</a></sup>. Based on our personal unpublished experience, 8 out of 10 patients with anti-TNF-refractory disease responded to ustekinumab but needed an augmented dosing schedule of every 4 to 6 weeks during maintenance to maintain a recommended trough level of &gt;4.5 mg/ml.</p><p class="" id=d18144e1084>The second agent in this group is risankizumab, a humanized IgG1 monoclonal antibody that selectively binds with high affinity to the IL-23 p19 subunit and is currently being studied for use in patients with IBD. By specifically targeting the IL-23-mediated inflammatory pathway and thus the T-helper 17 cells without disrupting the IL-12-dependent T-cell pathway, which is thought to be important for infection and cancer immunity, risankizumab theoretically may confer fewer side effects in comparison with ustekinumab<sup><a href="#ref-123">123</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e1094>JAK/STAT inhibitors</h2><p class="" id=d18144e1097>Janus kinases (JAKs) are intracellular signaling molecules that, when activated by cytokines, lead to phosphorylation and dimerization of Signal Transducer and Activator of Transcription proteins (STATs), which migrate into the nucleus and induce further gene transcription that modulates inflammation that is characteristic of IBD<sup><a href="#ref-144">144</a></sup>. The JAK/STAT pathway regulates intracellular signaling involving common gamma chain-containing cytokine receptors for interleukins 2, 4, 7, 9, 15, and 21<sup><a href="#ref-145">145</a></sup>. These cytokines and their downstream JAK/STAT signaling pathways are integral to lymphocyte activation, function, and proliferation. Inhibition of the JAK/STAT signaling pathway is a major area of interest in the development of novel IBD medications<sup><a href="#ref-146">146</a></sup>.</p><p class="" id=d18144e1112>Tofacitinib is an oral, small-molecule inhibitor of JAK1, JAK3, and, to a lesser extent, JAK2. In adults with UC, the rate of remission at 8 weeks was significantly higher in the 10 mg tofacitinib group than in the placebo group in the OCTAVE Induction 1 trial (18.5% versus 8.2%) and in the OCTAVE Induction 2 trial (16.6% versus 3.6%). In the OCTAVE Sustain trial, remission at 52 weeks occurred in 34.3% of patients in the 5 mg tofacitinib group and 40.6% in the 10 mg tofacitinib group compared to 11.1% in the placebo group (<i>P</i> &lt;0.001 for both comparisons with placebo). Side effects, especially rates of serious infection, were higher with tofacitinib than with placebo. However, in the OCTAVE Sustain trial, the rate of serious infection was similar across the three treatment groups, but the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo<sup><a href="#ref-147">147</a></sup>. Other side effects noticed include dyslipidemia (high HDL and LDL cholesterol) and increased risk of cardiovascular events and non-melanoma skin cancers<sup><a href="#ref-145">145</a></sup>. In a post hoc analysis of data from the OCTAVE trials, Hanauer <i>et al.</i><sup><a href="#ref-148">148</a></sup> reported significant improvements in stool frequency and rectal bleeding in UC patients within the first 3 days of induction therapy with tofacitinib compared with placebo. There are no data on the use of tofacitinib in pediatric patients, and it had poor efficacy in adults with CD<sup><a href="#ref-123">123</a></sup>.</p><p class="" id=d18144e1136>Filgotinib is a second agent in this group and is a highly selective JAK-1 inhibitor. In phase II clinical trials, filgotinib has been shown to be effective in CD and may be particularly useful in those with previous anti-TNF exposure<sup><a href="#ref-149">149</a></sup> (<a href="#T1">Table 1</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Medication, dosing, therapeutic drug monitoring, and references.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d18144e1157 class=n-a></a><thead><a name=d18144e1159 class=n-a></a><tr><a name=d18144e1161 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d18144e1163 class=n-a></a>Medication</th><th align=left colspan=1 rowspan=1 valign=top><a name=d18144e1166 class=n-a></a>Recommended dose for induction</th><th align=left colspan=1 rowspan=1 valign=top><a name=d18144e1169 class=n-a></a>Recommended dose for maintenance</th><th align=left colspan=1 rowspan=1 valign=top><a name=d18144e1172 class=n-a></a>Recommended trough levels for biological remission (μg/ml)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d18144e1175 class=n-a></a>Recommended trough levels for mucosal healing (μg/ml)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d18144e1179 class=n-a></a>Reference</th></tr></thead><tbody><a name=d18144e1183 class=n-a></a><tr><a name=d18144e1185 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1187 class=n-a></a>Infliximab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1190 class=n-a></a>5 mg/kg on week 0, 2, and 6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1193 class=n-a></a>5 mg/kg every 8 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1196 class=n-a></a>3–7</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1199 class=n-a></a>&gt;5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1203 class=n-a></a>78,95</td></tr><tr><a name=d18144e1207 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1209 class=n-a></a>Adalimumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1212 class=n-a></a>&lt;40 kg: 80 mg and 40 mg at week 0 and 2<br class=br>&gt;40 kg: 160 mg and 80 mg at week 0 and 2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1217 class=n-a></a>&lt;40 kg: 20 mg every 2 weeks<br class=br><br class=br>&gt;40 kg: 40 mg every 2 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1223 class=n-a></a>&gt;5.9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1226 class=n-a></a>&gt;7.5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1230 class=n-a></a>95,96</td></tr><tr><a name=d18144e1234 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1236 class=n-a></a>Golimumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1239 class=n-a></a>&lt;45 kg: 120 mg/m<sup>2</sup> on week 0 and 60 mg/m<sup>2</sup> on week 2<br class=br><br class=br>&gt;45 kg: 200 mg on week 0 and 100 mg on week 2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1251 class=n-a></a>&lt;45 kg: 60 mg/m<sup>2</sup> every 4 weeks<br class=br><br class=br>&gt;45 kg: 100 mg every 4 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1260 class=n-a></a>&gt;1.4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1263 class=n-a></a>NA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1267 class=n-a></a>95</td></tr><tr><a name=d18144e1271 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1273 class=n-a></a>Vedolizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1276 class=n-a></a>6 mg/kg on week 0, 2, and 6 (max 300)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1279 class=n-a></a>6 mg/kg every 8 weeks (max 300)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1282 class=n-a></a>&gt;13.6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1285 class=n-a></a>NA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1289 class=n-a></a>95</td></tr><tr><a name=d18144e1293 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1295 class=n-a></a>Ustekinumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1298 class=n-a></a>&lt;40 kg: 6 mg/kg<br class=br>40 to &lt;55 kg: 260 mg<br class=br>55 to &lt;85 kg: 390 mg<br class=br>&gt;85 kg: 520 mg</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1307 class=n-a></a>&lt;40 kg: 45 mg every 8 weeks<br class=br><br class=br>&gt;40 kg: 90 mg every 8 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1313 class=n-a></a>&gt;0.8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1316 class=n-a></a>&gt;4.5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d18144e1320 class=n-a></a>95</td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d18144e1330>Conclusion</h2><p class="" id=d18144e1333>Therapeutic discovery continues to teach us the many intricate and complex pathways of the human inflammatory response in IBD. We must be vigilant to the short-term and long-term effects of all of these medications, even with the new generation of gut-specific therapies. The identification of lymphoma associated with the TNF-α agents was recognized in post marketing surveillance. However, we must always frame the risk of these medications to our patients in the broader context of the natural history of this aggressive and progressive disease. As scientific discovery continues to push the envelope in defining our understanding of pediatric IBD, the current era of therapeutics gives us hope that a cure may be realized in the not-so-distant future.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d18144e1340 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d19117>References</h2><div class="section ref-list"><a name=d18144e1340 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d18144e1347 class=n-a></a>Benchimol EI, Fortinsky KJ, Gozdyra P, <i> et al.</i>: Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. <i>Inflamm Bowel Dis.</i> 2011; <b>17</b>(1): 423–39. <a target=xrefwindow id=d18144e1358 href="http://www.ncbi.nlm.nih.gov/pubmed/20564651">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1361 href="https://doi.org/10.1002/ibd.21349">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d18144e1370 class=n-a></a>Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, <i> et al.</i>: Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. <i>Inflamm Bowel Dis.</i> 2013; <b>19</b>(6): 1218–23. <a target=xrefwindow id=d18144e1381 href="http://www.ncbi.nlm.nih.gov/pubmed/23528339">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1384 href="https://doi.org/10.1097/MIB.0b013e318280b13e">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4898969">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d18144e1397 class=n-a></a>Malaty HM, Fan X, Opekun AR, <i> et al.</i>: Rising incidence of inflammatory bowel disease among children: a 12-year study. <i>J Pediatr Gastroenterol Nutr.</i> 2010; <b>50</b>(1): 27–31. <a target=xrefwindow id=d18144e1408 href="http://www.ncbi.nlm.nih.gov/pubmed/19934770">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1411 href="https://doi.org/10.1097/MPG.0b013e3181b99baa">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727521506"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e1420 class=n-a></a>Benchimol EI, Bernstein CN, Bitton A, <i> et al.</i>: Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. <i>Am J Gastroenterol.</i> 2017; <b>112</b>(7): 1120–34. <a target=xrefwindow id=d18144e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/28417994">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1434 href="https://doi.org/10.1038/ajg.2017.97">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1438 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5527278">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727521506">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d18144e1452 class=n-a></a>Carroll MW, Hamilton Z, Gill H, <i> et al.</i>: Pediatric Inflammatory Bowel Disease Among South Asians Living in British Columbia, Canada: A Distinct Clinical Phenotype. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(2): 387–96. <a target=xrefwindow id=d18144e1463 href="http://www.ncbi.nlm.nih.gov/pubmed/26752467">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1466 href="https://doi.org/10.1097/MIB.0000000000000651">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d18144e1476 class=n-a></a>Pinsk V, Lemberg DA, Grewal K, <i> et al.</i>: Inflammatory bowel disease in the South Asian pediatric population of British Columbia. <i>Am J Gastroenterol.</i> 2007; <b>102</b>(5): 1077–83. <a target=xrefwindow id=d18144e1487 href="http://www.ncbi.nlm.nih.gov/pubmed/17378907">PubMed Abstract </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d18144e1496 class=n-a></a>Abramson O, Durant M, Mow W, <i> et al.</i>: Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. <i>J Pediatr.</i> 2010; <b>157</b>(2): 233–239.e1. <a target=xrefwindow id=d18144e1507 href="http://www.ncbi.nlm.nih.gov/pubmed/20400099">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1510 href="https://doi.org/10.1016/j.jpeds.2010.02.024">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d18144e1519 class=n-a></a>Armitage EL, Aldhous MC, Anderson N, <i> et al.</i>: Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. <i>Gastroenterology.</i> 2004; <b>127</b>(4): 1051–7. <a target=xrefwindow id=d18144e1530 href="http://www.ncbi.nlm.nih.gov/pubmed/15480983">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1533 href="https://doi.org/10.1053/j.gastro.2004.06.024">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d18144e1542 class=n-a></a>Jussila A, Virta LJ, Salomaa V, <i> et al.</i>: High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. <i>J Crohns Colitis.</i> 2013; <b>7</b>(7): e256–e262. <a target=xrefwindow id=d18144e1553 href="http://www.ncbi.nlm.nih.gov/pubmed/23140840">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1556 href="https://doi.org/10.1016/j.crohns.2012.10.007">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d18144e1565 class=n-a></a>Burisch J, Pedersen N, Čuković-Čavka S, <i> et al.</i>: East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. <i>Gut.</i> 2014; <b>63</b>(4): 588–97. <a target=xrefwindow id=d18144e1576 href="http://www.ncbi.nlm.nih.gov/pubmed/23604131">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1579 href="https://doi.org/10.1136/gutjnl-2013-304636">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d18144e1588 class=n-a></a>Gordon H, Trier Moller F, Andersen V, <i> et al.</i>: Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies. <i>Inflamm Bowel Dis.</i> 2015; <b>21</b>(6): 1428–34. <a target=xrefwindow id=d18144e1599 href="http://www.ncbi.nlm.nih.gov/pubmed/25895112">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1602 href="https://doi.org/10.1097/MIB.0000000000000393">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1606 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4450891">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725717456"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e1616 class=n-a></a>Molodecky NA, Soon IS, Rabi DM, <i> et al.</i>: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. <i>Gastroenterology.</i> 2012; <b>142</b>(1): 46–54.e42. quiz e30. <a target=xrefwindow id=d18144e1627 href="http://www.ncbi.nlm.nih.gov/pubmed/22001864">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1630 href="https://doi.org/10.1053/j.gastro.2011.10.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725717456">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d18144e1644 class=n-a></a>Kamm MA: Rapid changes in epidemiology of inflammatory bowel disease. <i>Lancet.</i> 2018; <b>390</b>(10114): 2741–2. <a target=xrefwindow id=d18144e1652 href="http://www.ncbi.nlm.nih.gov/pubmed/29050647">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1655 href="https://doi.org/10.1016/S0140-6736(17)32669-7">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725658435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e1664 class=n-a></a>Liu JZ, van Sommeren S, Huang H, <i> et al.</i>: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. <i>Nat Genet.</i> 2015; <b>47</b>(9): 979–86. <a target=xrefwindow id=d18144e1675 href="http://www.ncbi.nlm.nih.gov/pubmed/26192919">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1678 href="https://doi.org/10.1038/ng.3359">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1682 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881818">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725658435">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717961892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e1696 class=n-a></a>Jostins L, Ripke S, Weersma RK, <i> et al.</i>: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature.</i> 2012; <b>491</b>(7422): 119–24. <a target=xrefwindow id=d18144e1707 href="http://www.ncbi.nlm.nih.gov/pubmed/23128233">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1710 href="https://doi.org/10.1038/nature11582">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1714 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3491803">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717961892">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d18144e1728 class=n-a></a>Rutgeerts P, Feagan BG, Lichtenstein GR, <i> et al.</i>: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. <i>Gastroenterology.</i> 2004; <b>126</b>(2): 402–13. <a target=xrefwindow id=d18144e1739 href="http://www.ncbi.nlm.nih.gov/pubmed/14762776">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1742 href="https://doi.org/10.1053/j.gastro.2003.11.014">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2082970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e1751 class=n-a></a>Baert F, Moortgat L, van Assche G, <i> et al.</i>: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. <i>Gastroenterology.</i> 2010; <b>138</b>(4): 463–8. quiz e10–1. <a target=xrefwindow id=d18144e1762 href="http://www.ncbi.nlm.nih.gov/pubmed/19818785">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1765 href="https://doi.org/10.1053/j.gastro.2009.09.056">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2082970">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d18144e1780 class=n-a></a>Chang S, Malter L, Hudesman D: Disease monitoring in inflammatory bowel disease. <i>World J Gastroenterol.</i> 2015; <b>21</b>(40): 11246–59. <a target=xrefwindow id=d18144e1788 href="http://www.ncbi.nlm.nih.gov/pubmed/26523100">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1791 href="https://doi.org/10.3748/wjg.v21.i40.11246">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1794 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4616202">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d18144e1803 class=n-a></a>Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? <i>Gut.</i> 2006; <b>55</b>(3): 426–31. <a target=xrefwindow id=d18144e1811 href="http://www.ncbi.nlm.nih.gov/pubmed/16474109">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1814 href="https://doi.org/10.1136/gut.2005.069476">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1817 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1856093">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d18144e1826 class=n-a></a>Dubinsky MC, Kugathasan S, Mei L, <i> et al.</i>: Increased immune reactivity predicts aggressive complicating Crohn's disease in children. <i>Clin Gastroenterol Hepatol.</i> 2008; <b>6</b>(10): 1105–11. <a target=xrefwindow id=d18144e1837 href="http://www.ncbi.nlm.nih.gov/pubmed/18619921">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1840 href="https://doi.org/10.1016/j.cgh.2008.04.032">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1844 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3745777">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d18144e1853 class=n-a></a>Dubinsky M: Can serologic markers help determine prognosis and guide therapy? <i>Dig Dis.</i> 2010; <b>28</b>(3): 424–8. <a target=xrefwindow id=d18144e1861 href="http://www.ncbi.nlm.nih.gov/pubmed/20926867">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1864 href="https://doi.org/10.1159/000320397">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d18144e1873 class=n-a></a>Adler J, Rangwalla SC, Dwamena BA, <i> et al.</i>: The prognostic power of the NOD2 genotype for complicated Crohn's disease: A meta-analysis. <i>Am J Gastroenterol.</i> 2011; <b>106</b>(4): 699–712. <a target=xrefwindow id=d18144e1884 href="http://www.ncbi.nlm.nih.gov/pubmed/21343918">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1887 href="https://doi.org/10.1038/ajg.2011.19">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d18144e1896 class=n-a></a>Solon JG, Burke JP, Walsh SR, <i> et al.</i>: The effect of NOD2 polymorphism on postsurgical recurrence in Crohn's disease: A systematic review and meta-analysis of available literature. <i>Inflamm Bowel Dis.</i> 2013; <b>19</b>(5): 1099–105. <a target=xrefwindow id=d18144e1907 href="http://www.ncbi.nlm.nih.gov/pubmed/23493074">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1910 href="https://doi.org/10.1097/MIB.0b013e3182813391">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727372624"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e1920 class=n-a></a>Kugathasan S, Denson LA, Walters TD, <i> et al.</i>: Prediction of complicated disease course for children newly diagnosed with Crohn's disease: A multicentre inception cohort study. <i>Lancet.</i> 2017; <b>389</b>(10080): 1710–8. <a target=xrefwindow id=d18144e1931 href="http://www.ncbi.nlm.nih.gov/pubmed/28259484">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1934 href="https://doi.org/10.1016/S0140-6736(17)30317-3">Publisher Full Text </a> | <a target=xrefwindow id=d18144e1938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5719489">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727372624">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d18144e1951 class=n-a></a>Siegel CA, Horton H, Siegel LS, <i> et al.</i>: A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. <i>Aliment Pharmacol Ther.</i> 2016; <b>43</b>(2): 262–71. <a target=xrefwindow id=d18144e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/26567467">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1965 href="https://doi.org/10.1111/apt.13460">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d18144e1974 class=n-a></a>Rubio A, Pigneur B, Garnier-Lengliné H, <i> et al.</i>: The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. <i>Aliment Pharmacol Ther.</i> 2011; <b>33</b>(12): 1332–9. <a target=xrefwindow id=d18144e1985 href="http://www.ncbi.nlm.nih.gov/pubmed/21507029">PubMed Abstract </a> | <a target=xrefwindow id=d18144e1988 href="https://doi.org/10.1111/j.1365-2036.2011.04662.x">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d18144e1997 class=n-a></a>Buchanan E, Gaunt WW, Cardigan T, <i> et al.</i>: The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. <i>Aliment Pharmacol Ther.</i> 2009; <b>30</b>(5): 501–7. <a target=xrefwindow id=d18144e2008 href="http://www.ncbi.nlm.nih.gov/pubmed/19549288">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2011 href="https://doi.org/10.1111/j.1365-2036.2009.04067.x">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d18144e2020 class=n-a></a>Borrelli O, Cordischi L, Cirulli M, <i> et al.</i>: Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: A randomized controlled open-label trial. <i>Clin Gastroenterol Hepatol.</i> 2006; <b>4</b>(6): 744–53. <a target=xrefwindow id=d18144e2031 href="http://www.ncbi.nlm.nih.gov/pubmed/16682258">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2034 href="https://doi.org/10.1016/j.cgh.2006.03.010">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d18144e2043 class=n-a></a>Fell JM, Paintin M, Arnaud-Battandier F, <i> et al.</i>: Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2000; <b>14</b>(3): 281–9. <a target=xrefwindow id=d18144e2054 href="http://www.ncbi.nlm.nih.gov/pubmed/10735920">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2057 href="https://doi.org/10.1046/j.1365-2036.2000.00707.x">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d18144e2067 class=n-a></a>Whitten KE, Leach ST, Bohane TD, <i> et al.</i>: Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. <i>J Gastroenterol.</i> 2010; <b>45</b>(4): 399–405. <a target=xrefwindow id=d18144e2078 href="http://www.ncbi.nlm.nih.gov/pubmed/19957194">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2081 href="https://doi.org/10.1007/s00535-009-0165-0">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d18144e2090 class=n-a></a>Gerasimidis K, Talwar D, Duncan A, <i> et al.</i>: Impact of exclusive enteral nutrition on body composition and circulating micronutrients in plasma and erythrocytes of children with active Crohn's disease. <i>Inflamm Bowel Dis.</i> 2012; <b>18</b>(9): 1672–81. <a target=xrefwindow id=d18144e2101 href="http://www.ncbi.nlm.nih.gov/pubmed/22069243">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2104 href="https://doi.org/10.1002/ibd.21916">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d18144e2113 class=n-a></a>Critch J, Day AS, Otley A, <i> et al.</i>: Use of Enteral Nutrition for the Control of Intestinal Inflammation in Pediatric Crohn Disease. <i>J Pediatr Gastroenterol Nutr.</i> 2012; <b>54</b>(2): 298–305. <a target=xrefwindow id=d18144e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/22002478">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2127 href="https://doi.org/10.1097/MPG.0b013e318235b397">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d18144e2136 class=n-a></a>Ruemmele FM, Veres G, Kolho KL, <i> et al.</i>: Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. <i>J Crohns Colitis.</i> 2014; <b>8</b>(10): 1179–207. <a target=xrefwindow id=d18144e2147 href="http://www.ncbi.nlm.nih.gov/pubmed/24909831">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2150 href="https://doi.org/10.1016/j.crohns.2014.04.005">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d18144e2159 class=n-a></a>Afzal NA, Davies S, Paintin M, <i> et al.</i>: Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. <i>Dig Dis Sci.</i> 2005; <b>50</b>(8): 1471–5. <a target=xrefwindow id=d18144e2170 href="http://www.ncbi.nlm.nih.gov/pubmed/16110838">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2173 href="https://doi.org/10.1007/s10620-005-2864-6">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d18144e2182 class=n-a></a>Swaminath A, Feathers A, Ananthakrishnan AN, <i> et al.</i>: Systematic review with meta-analysis: Enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2017; <b>46</b>(7): 645–56. <a target=xrefwindow id=d18144e2193 href="http://www.ncbi.nlm.nih.gov/pubmed/28815649">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2196 href="https://doi.org/10.1111/apt.14253">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2200 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5798240">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d18144e2210 class=n-a></a>Leach ST, Mitchell HM, Eng WR, <i> et al.</i>: Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2008; <b>28</b>(6): 724–33. <a target=xrefwindow id=d18144e2221 href="http://www.ncbi.nlm.nih.gov/pubmed/19145728">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2224 href="https://doi.org/10.1111/j.1365-2036.2008.03796.x">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d18144e2233 class=n-a></a>Ashton JJ, Gavin J, Beattie RM: Exclusive enteral nutrition in Crohn's disease: Evidence and practicalities. <i>Clin Nutr.</i> 2019; <b>38</b>(1): 80–9. <a target=xrefwindow id=d18144e2241 href="http://www.ncbi.nlm.nih.gov/pubmed/29398336">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2244 href="https://doi.org/10.1016/j.clnu.2018.01.020">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d18144e2253 class=n-a></a>Suskind DL, Wahbeh G, Gregory N, <i> et al.</i>: Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. <i>J Pediatr Gastroenterol Nutr.</i> 2014; <b>58</b>(1): 87–91. <a target=xrefwindow id=d18144e2264 href="http://www.ncbi.nlm.nih.gov/pubmed/24048168">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2267 href="https://doi.org/10.1097/MPG.0000000000000103">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d18144e2276 class=n-a></a>Suskind DL, Wahbeh G, Cohen SA, <i> et al.</i>: Patients Perceive Clinical Benefit with the Specific Carbohydrate Diet for Inflammatory Bowel Disease. <i>Dig Dis Sci.</i> 2016; <b>61</b>(11): 3255–60. <a target=xrefwindow id=d18144e2287 href="http://www.ncbi.nlm.nih.gov/pubmed/27638834">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2290 href="https://doi.org/10.1007/s10620-016-4307-y">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731389161"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e2299 class=n-a></a>Braly K, Williamson N, Shaffer ML, <i> et al.</i>: Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease. <i>J Pediatr Gastroenterol Nutr.</i> 2017; <b>65</b>(5): 533–8. <a target=xrefwindow id=d18144e2310 href="http://www.ncbi.nlm.nih.gov/pubmed/28825603">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2313 href="https://doi.org/10.1097/MPG.0000000000001613">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2317 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5653423">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731389161">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d18144e2330 class=n-a></a>Cohen SA, Gold BD, Oliva S, <i> et al.</i>: Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. <i>J Pediatr Gastroenterol Nutr.</i> 2014; <b>59</b>(4): 516–21. <a target=xrefwindow id=d18144e2341 href="http://www.ncbi.nlm.nih.gov/pubmed/24897165">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2344 href="https://doi.org/10.1097/MPG.0000000000000449">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735919047"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e2354 class=n-a></a>Levine A, Wine E, Assa A, <i> et al.</i>: Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. <i>Gastroenterology.</i> 2019; <b>157</b>(2): 440–450.e8. <a target=xrefwindow id=d18144e2365 href="http://www.ncbi.nlm.nih.gov/pubmed/31170412">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2368 href="https://doi.org/10.1053/j.gastro.2019.04.021">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735919047">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734634906"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e2381 class=n-a></a>Svolos V, Hansen R, Nichols B, <i> et al.</i>: Treatment of Active Crohn’s Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. <i>Gastroenterology.</i> 2019; <b>156</b>(5): 1354–1367.e6. <a target=xrefwindow id=d18144e2392 href="http://www.ncbi.nlm.nih.gov/pubmed/30550821">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2395 href="https://doi.org/10.1053/j.gastro.2018.12.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734634906">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d18144e2408 class=n-a></a>Sabino J, Lewis JD, Colombel JF, <i> et al.</i>: Treating Inflammatory Bowel Disease With Diet: A Taste Test. <i>Gastroenterology.</i> 2019; <b>157</b>(2): 295–7. <a target=xrefwindow id=d18144e2419 href="http://www.ncbi.nlm.nih.gov/pubmed/31254503">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2422 href="https://doi.org/10.1053/j.gastro.2019.06.027">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d18144e2431 class=n-a></a>Olendzki BC, Silverstein TD, Persuitte GM, <i> et al.</i>: An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. <i>Nutr J.</i> 2014; <b>13</b>: 5. <a target=xrefwindow id=d18144e2442 href="http://www.ncbi.nlm.nih.gov/pubmed/24428901">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2445 href="https://doi.org/10.1186/1475-2891-13-5">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2449 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3896778">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d18144e2458 class=n-a></a>Prince AC, Myers CE, Joyce T, <i> et al.</i>: Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(5): 1129–36. <a target=xrefwindow id=d18144e2469 href="http://www.ncbi.nlm.nih.gov/pubmed/26914438">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2472 href="https://doi.org/10.1097/MIB.0000000000000708">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d18144e2481 class=n-a></a>Lim WC, Wang Y, MacDonald JK, <i> et al.</i>: Aminosalicylates for induction of remission or response in Crohn's disease. <i>Cochrane Database Syst Rev.</i> 2016; <b>7</b>: CD008870. <a target=xrefwindow id=d18144e2492 href="http://www.ncbi.nlm.nih.gov/pubmed/27372735">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2495 href="https://doi.org/10.1002/14651858.CD008870.pub2">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2499 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6457996">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d18144e2509 class=n-a></a>Gordon M, Naidoo K, Thomas AG, <i> et al.</i>: Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. <i>Cochrane Database Syst Rev.</i> 2011; (1): CD008414. <a target=xrefwindow id=d18144e2517 href="http://www.ncbi.nlm.nih.gov/pubmed/21249709">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2520 href="https://doi.org/10.1002/14651858.CD008414.pub2">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d18144e2529 class=n-a></a>Lim WC, Hanauer S: Aminosalicylates for induction of remission or response in Crohn's disease. <i>Cochrane Database Syst Rev.</i> 2010; (12): CD008870. <a target=xrefwindow id=d18144e2534 href="http://www.ncbi.nlm.nih.gov/pubmed/21154400">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2537 href="https://doi.org/10.1002/14651858.CD008870">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d18144e2546 class=n-a></a>Akobeng AK, Zhang D, Gordon M, <i> et al.</i>: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. <i>Cochrane Database Syst Rev.</i> 2016; <b>9</b>: CD003715. <a target=xrefwindow id=d18144e2557 href="http://www.ncbi.nlm.nih.gov/pubmed/27681657">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2560 href="https://doi.org/10.1002/14651858.CD003715.pub3">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2564 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6457838">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d18144e2573 class=n-a></a>Turner D, Ruemmele FM, Orlanski-Meyer E, <i> et al.</i>: Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care- an Evidence-Based Guideline from ECCO and ESPGHAN. <i>J Pediatr Gastroenterol Nutr.</i> 2018; <b>67</b>: 257–91. <a target=xrefwindow id=d18144e2584 href="http://www.ncbi.nlm.nih.gov/pubmed/29851766">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2587 href="https://doi.org/10.1097/MPG.0000000000002035">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d18144e2596 class=n-a></a>Levine A, Yerushalmi B, Kori M, <i> et al.</i>: Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study. <i>J Crohns Colitis.</i> 2017; <b>11</b>(8): 970–4. <a target=xrefwindow id=d18144e2607 href="http://www.ncbi.nlm.nih.gov/pubmed/28369299">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2610 href="https://doi.org/10.1093/ecco-jcc/jjx042">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d18144e2619 class=n-a></a>Turner D, Yerushalmi B, Kori M, <i> et al.</i>: Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. <i>J Crohns Colitis.</i> 2017; <b>11</b>(5): 527–33. <a target=xrefwindow id=d18144e2630 href="http://www.ncbi.nlm.nih.gov/pubmed/28453754">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2633 href="https://doi.org/10.1093/ecco-jcc/jjw180">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d18144e2643 class=n-a></a>Wang Y, Parker CE, Bhanji T, <i> et al.</i>: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>Cochrane Database Syst Rev.</i> 2016; <b>4</b>: CD000543. <a target=xrefwindow id=d18144e2654 href="http://www.ncbi.nlm.nih.gov/pubmed/27101467">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2657 href="https://doi.org/10.1002/14651858.CD000543.pub4">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d18144e2666 class=n-a></a>Wang Y, Parker CE, Feagan BG, <i> et al.</i>: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>Cochrane Database Syst Rev.</i> 2016; (5): CD00054. <a target=xrefwindow id=d18144e2674 href="http://www.ncbi.nlm.nih.gov/pubmed/27158764">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2677 href="https://doi.org/10.1002/14651858.CD000544.pub4">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d18144e2686 class=n-a></a>Lang A, Salomon N, Wu JC, <i> et al.</i>: Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. <i>Clin Gastroenterol Hepatol.</i> 2015; <b>13</b>(8): 1444–9.e1. <a target=xrefwindow id=d18144e2697 href="http://www.ncbi.nlm.nih.gov/pubmed/25724700">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2700 href="https://doi.org/10.1016/j.cgh.2015.02.019">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d18144e2709 class=n-a></a>Boyle BM, Kappelman MD, Colletti RB, <i> et al.</i>: Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. <i>World J Gastroenterol.</i> 2014; <b>20</b>(27): 9185–90. <a target=xrefwindow id=d18144e2720 href="http://www.ncbi.nlm.nih.gov/pubmed/25083093">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2723 href="https://doi.org/10.3748/wjg.v20.i27.9185">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2727 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4112859">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d18144e2736 class=n-a></a>Zitomersky NL, Bousvaros A: Medical therapies for Crohn disease in children and adolescents. In: UpToDate. UpToDate, Waltham, MA. <a target=xrefwindow id=d18144e2738 href="https://www.uptodate.com/contents/medical-therapies-for-crohn-disease-in-children-and-adolescents">Reference Source</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d18144e2747 class=n-a></a>Hanauer SB: What to take from TREAT? <i>Am J Gastroenterol.</i> 2012; <b>107</b>(9): 1423–5. <a target=xrefwindow id=d18144e2755 href="http://www.ncbi.nlm.nih.gov/pubmed/22951879">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2758 href="https://doi.org/10.1038/ajg.2012.224">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d18144e2768 class=n-a></a>Konidari A, Anagnostopoulos A, Bonnett LJ, <i> et al.</i>: Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. <i>Br J Clin Pharmacol.</i> 2014; <b>78</b>(3): 467–76. <a target=xrefwindow id=d18144e2779 href="http://www.ncbi.nlm.nih.gov/pubmed/24592889">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2782 href="https://doi.org/10.1111/bcp.12365">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2786 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4243898">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d18144e2795 class=n-a></a>Gearry RB, Barclay ML: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. <i>J Gastroenterol Hepatol.</i> 2005; <b>20</b>(8): 1149–57. <a target=xrefwindow id=d18144e2803 href="http://www.ncbi.nlm.nih.gov/pubmed/16048561">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2806 href="https://doi.org/10.1111/j.1440-1746.2005.03832.x">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d18144e2815 class=n-a></a>Lichtenstein GR: Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. <i>Gastroenterology.</i> 2004; <b>127</b>(5): 1558–64. <a target=xrefwindow id=d18144e2823 href="http://www.ncbi.nlm.nih.gov/pubmed/15521022">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2826 href="https://doi.org/10.1053/j.gastro.2004.09.061">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d18144e2835 class=n-a></a>Markowitz J, Grancher K, Kohn N, <i> et al.</i>: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. <i>Gastroenterology.</i> 2000; <b>119</b>(4): 895–902. <a target=xrefwindow id=d18144e2846 href="http://www.ncbi.nlm.nih.gov/pubmed/11040176">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2849 href="https://doi.org/10.1053/gast.2000.18144">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d18144e2858 class=n-a></a>Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. <i>Gastroenterology.</i> 1998; <b>115</b>(4): 813–21. <a target=xrefwindow id=d18144e2866 href="http://www.ncbi.nlm.nih.gov/pubmed/9753482">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2869 href="https://doi.org/10.1016/s0016-5085(98)70251-3">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d18144e2878 class=n-a></a>Israeli E, Goldin E, Fishman S, <i> et al.</i>: Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. <i>Clin Exp Immunol.</i> 2015; <b>181</b>(2): 362–72. <a target=xrefwindow id=d18144e2889 href="http://www.ncbi.nlm.nih.gov/pubmed/25846055">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2892 href="https://doi.org/10.1111/cei.12640">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4516452">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d18144e2906 class=n-a></a>McDonald JW, Tsoulis DJ, MacDonald JK, <i> et al.</i>: Methotrexate for induction of remission in refractory Crohn's disease. <i>Cochrane Database Syst Rev.</i> 2012; <b>12</b>: CD003459. <a target=xrefwindow id=d18144e2917 href="http://www.ncbi.nlm.nih.gov/pubmed/23235598">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2920 href="https://doi.org/10.1002/14651858.CD003459.pub3">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d18144e2929 class=n-a></a>Patel V, Wang Y, MacDonald JK, <i> et al.</i>: Methotrexate for maintenance of remission in Crohn's disease. <i>Cochrane Database Syst Rev.</i> 2014; (8): CD006884. <a target=xrefwindow id=d18144e2937 href="http://www.ncbi.nlm.nih.gov/pubmed/25157445">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2940 href="https://doi.org/10.1002/14651858.CD006884.pub3">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d18144e2949 class=n-a></a>Chande N, Wang Y, MacDonald JK, <i> et al.</i>: Methotrexate for induction of remission in ulcerative colitis. <i>Cochrane Database Syst Rev.</i> 2014; (8): CD006618. <a target=xrefwindow id=d18144e2957 href="http://www.ncbi.nlm.nih.gov/pubmed/25162749">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2960 href="https://doi.org/10.1002/14651858.CD006618.pub3">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2963 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6486224">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725713055"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e2972 class=n-a></a>Wang Y, MacDonald JK, Vandermeer B, <i> et al.</i>: Methotrexate for maintenance of remission in ulcerative colitis. <i>Cochrane Database Syst Rev.</i> 2015; (8): CD007560. <a target=xrefwindow id=d18144e2980 href="http://www.ncbi.nlm.nih.gov/pubmed/26263042">PubMed Abstract </a> | <a target=xrefwindow id=d18144e2983 href="https://doi.org/10.1002/14651858.CD007560.pub3">Publisher Full Text </a> | <a target=xrefwindow id=d18144e2986 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6486092">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725713055">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d18144e2999 class=n-a></a>Herfarth H, Barnes EL, Valentine JF, <i> et al.</i>: Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. <i>Gastroenterology.</i> 2018; <b>155</b>(4): 1098–1108.e9. <a target=xrefwindow id=d18144e3010 href="http://www.ncbi.nlm.nih.gov/pubmed/29964043">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3013 href="https://doi.org/10.1053/j.gastro.2018.06.046">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3017 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6174092">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d18144e3026 class=n-a></a>Colman RJ, Lawton RC, Dubinsky MC, <i> et al.</i>: Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. <i>Inflamm Bowel Dis.</i> 2018; <b>24</b>(10): 2135–41. <a target=xrefwindow id=d18144e3037 href="http://www.ncbi.nlm.nih.gov/pubmed/29688409">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3040 href="https://doi.org/10.1093/ibd/izy078">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d18144e3050 class=n-a></a>Feagan BG, Rochon J, Fedorak RN, <i> et al.</i>: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. <i>N Engl J Med.</i> 1995; <b>332</b>(5): 292–7. <a target=xrefwindow id=d18144e3061 href="http://www.ncbi.nlm.nih.gov/pubmed/7816064">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3064 href="https://doi.org/10.1056/NEJM199502023320503">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d18144e3073 class=n-a></a>Bianchi G, Caporali R, Todoerti M, <i> et al.</i>: Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration. <i>Adv Ther.</i> 2016; <b>33</b>(3): 369–78. <a target=xrefwindow id=d18144e3084 href="http://www.ncbi.nlm.nih.gov/pubmed/26846283">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3087 href="https://doi.org/10.1007/s12325-016-0295-8">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3091 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4833794">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d18144e3100 class=n-a></a>Valentino PL, Church PC, Shah PS, <i> et al.</i>: Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. <i>Inflamm Bowel Dis.</i> 2014; <b>20</b>(1): 47–59. <a target=xrefwindow id=d18144e3111 href="http://www.ncbi.nlm.nih.gov/pubmed/24280876">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3114 href="https://doi.org/10.1097/01.MIB.0000436953.88522.3e">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d18144e3123 class=n-a></a>Shea B, Swinden MV, Ghogomu ET, <i> et al.</i>: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. <i>J Rheumatol.</i> 2014; <b>41</b>(6): 1049–60. <a target=xrefwindow id=d18144e3134 href="http://www.ncbi.nlm.nih.gov/pubmed/24737913">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3137 href="https://doi.org/10.3899/jrheum.130738">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d18144e3146 class=n-a></a>Ortiz Z, Shea B, Suarez Almazor M, <i> et al.</i>: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. <i>Cochrane Database Syst Rev.</i> 2000; (2): CD000951. <a target=xrefwindow id=d18144e3154 href="http://www.ncbi.nlm.nih.gov/pubmed/10796393">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3157 href="https://doi.org/10.1002/14651858.CD000951">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d18144e3166 class=n-a></a>Hyams J, Crandall W, Kugathasan S, <i> et al.</i>: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. <i>Gastroenterology.</i> 2007; <b>132</b>(3): 863–73; quiz 1165–6. <a target=xrefwindow id=d18144e3177 href="http://www.ncbi.nlm.nih.gov/pubmed/17324398">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3180 href="https://doi.org/10.1053/j.gastro.2006.12.003">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d18144e3190 class=n-a></a>Singh N, Rosenthal CJ, Melmed GY, <i> et al.</i>: Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. <i>Inflamm Bowel Dis.</i> 2014; <b>20</b>(10): 1708–13. <a target=xrefwindow id=d18144e3201 href="http://www.ncbi.nlm.nih.gov/pubmed/25153505">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3204 href="https://doi.org/10.1097/MIB.0000000000000137">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d18144e3213 class=n-a></a>Vande Casteele N, Khanna R, Levesque BG, <i> et al.</i>: The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. <i>Gut.</i> 2015; <b>64</b>(10): 1539–45. <a target=xrefwindow id=d18144e3224 href="http://www.ncbi.nlm.nih.gov/pubmed/25336114">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3227 href="https://doi.org/10.1136/gutjnl-2014-307883">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3231 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4602247">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d18144e3240 class=n-a></a>Hyams JS, Lerer T, Griffiths A, <i> et al.</i>: Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. <i>Inflamm Bowel Dis.</i> 2009; <b>15</b>(6): 816–22. <a target=xrefwindow id=d18144e3251 href="http://www.ncbi.nlm.nih.gov/pubmed/19107783">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3254 href="https://doi.org/10.1002/ibd.20845">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d18144e3263 class=n-a></a>Hyams J, Damaraju L, Blank M, <i> et al.</i>: Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. <i>Clin Gastroenterol Hepatol.</i> 2012; <b>10</b>(4): 391–399.e1. <a target=xrefwindow id=d18144e3274 href="http://www.ncbi.nlm.nih.gov/pubmed/22155755">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3277 href="https://doi.org/10.1016/j.cgh.2011.11.026">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d18144e3286 class=n-a></a>Vande Casteele N, Gils A: Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn’s Disease: Avoiding Failure While Lowering Costs? <i>Dig Dis Sci.</i> 2015; <b>60</b>(9): 2571–3. <a target=xrefwindow id=d18144e3294 href="http://www.ncbi.nlm.nih.gov/pubmed/25917050">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3297 href="https://doi.org/10.1007/s10620-015-3673-1">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d18144e3306 class=n-a></a>Levesque BG, Greenberg GR, Zou G, <i> et al.</i>: A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2014; <b>39</b>(10): 1126–35. <a target=xrefwindow id=d18144e3317 href="http://www.ncbi.nlm.nih.gov/pubmed/24689499">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3320 href="https://doi.org/10.1111/apt.12733">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d18144e3330 class=n-a></a>Fasanmade AA, Adedokun OJ, Blank M, <i> et al.</i>: Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. <i>Clin Ther.</i> 2011; <b>33</b>(7): 946–64. <a target=xrefwindow id=d18144e3341 href="http://www.ncbi.nlm.nih.gov/pubmed/21741088">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3344 href="https://doi.org/10.1016/j.clinthera.2011.06.002">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d18144e3353 class=n-a></a>Frymoyer A, Piester TL, Park KT: Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease. <i>J Pediatr Gastroenterol Nutr.</i> 2016; <b>62</b>(5): 723–7. <a target=xrefwindow id=d18144e3361 href="http://www.ncbi.nlm.nih.gov/pubmed/26890885">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3364 href="https://doi.org/10.1097/MPG.0000000000001123">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3367 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4842177">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728770716"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3376 class=n-a></a>Papamichael K, Vande Casteele N, Ferrante M, <i> et al.</i>: Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(9): 1510–5. <a target=xrefwindow id=d18144e3387 href="http://www.ncbi.nlm.nih.gov/pubmed/28816757">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3390 href="https://doi.org/10.1097/MIB.0000000000001231">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728770716">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d18144e3403 class=n-a></a>Adedokun OJ, Xu Z, Padgett L, <i> et al.</i>: Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. <i>Inflamm Bowel Dis.</i> 2013; <b>19</b>(13): 2753–62. <a target=xrefwindow id=d18144e3414 href="http://www.ncbi.nlm.nih.gov/pubmed/24193155">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3417 href="https://doi.org/10.1097/01.MIB.0000435438.84365.f7">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727213976"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3426 class=n-a></a>Hofmekler T, Bertha M, McCracken C, <i> et al.</i>: Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. <i>J Pediatr Gastroenterol Nutr.</i> 2017; <b>64</b>(4): 580–5. <a target=xrefwindow id=d18144e3437 href="http://www.ncbi.nlm.nih.gov/pubmed/28079601">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3440 href="https://doi.org/10.1097/MPG.0000000000001302">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727213976">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717954169"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3453 class=n-a></a>Hyams JS, Griffiths A, Markowitz J, <i> et al.</i>: Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. <i>Gastroenterology.</i> 2012; <b>143</b>(2): 365–374.e2. <a target=xrefwindow id=d18144e3464 href="http://www.ncbi.nlm.nih.gov/pubmed/22562021">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3467 href="https://doi.org/10.1053/j.gastro.2012.04.046">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717954169">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d18144e3481 class=n-a></a>Dubinsky MC, Rosh J, Faubion WA Jr, <i> et al.</i>: Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(4): 886–93. <a target=xrefwindow id=d18144e3492 href="http://www.ncbi.nlm.nih.gov/pubmed/26950307">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3495 href="https://doi.org/10.1097/MIB.0000000000000715">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3499 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4794130">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727246973"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3508 class=n-a></a>Faubion WA, Dubinsky M, Ruemmele FM, <i> et al.</i>: Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(3): 453–60. <a target=xrefwindow id=d18144e3519 href="http://www.ncbi.nlm.nih.gov/pubmed/28129288">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3522 href="https://doi.org/10.1097/MIB.0000000000001021">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3526 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5319394">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727246973">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d18144e3539 class=n-a></a>Dziechciarz P, Horvath A, Kierkuś J: Efficacy and Safety of Adalimumab for Paediatric Crohn's Disease: A Systematic Review. <i>J Crohns Colitis.</i> 2016; <b>10</b>(10): 1237–44. <a target=xrefwindow id=d18144e3547 href="http://www.ncbi.nlm.nih.gov/pubmed/26995184">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3550 href="https://doi.org/10.1093/ecco-jcc/jjw077">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d18144e3559 class=n-a></a>Thorlund K, Druyts E, Mills EJ, <i> et al.</i>: Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. <i>J Crohns Colitis.</i> 2014; <b>8</b>(7): 571–81. <a target=xrefwindow id=d18144e3570 href="http://www.ncbi.nlm.nih.gov/pubmed/24491514">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3573 href="https://doi.org/10.1016/j.crohns.2014.01.010">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d18144e3582 class=n-a></a>Volonaki E, Mutalib M, Kiparissi F, <i> et al.</i>: Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. <i>Eur J Gastroenterol Hepatol.</i> 2015; <b>27</b>(12): 1425–8. <a target=xrefwindow id=d18144e3593 href="http://www.ncbi.nlm.nih.gov/pubmed/26426835">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3596 href="https://doi.org/10.1097/MEG.0000000000000470">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735431918"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3605 class=n-a></a>Papamichael K, Cheifetz AS, Melmed GY, <i> et al.</i>: Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(9): 1655–1668.e3. <a target=xrefwindow id=d18144e3616 href="http://www.ncbi.nlm.nih.gov/pubmed/30928454">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3619 href="https://doi.org/10.1016/j.cgh.2019.03.037">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3623 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6661210">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735431918">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d18144e3637 class=n-a></a>Feuerstein JD, Nguyen GC, Kupfer SS, <i> et al.</i>: American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. <i>Gastroenterology.</i> 2017; <b>153</b>(3): 827–34. <a target=xrefwindow id=d18144e3648 href="http://www.ncbi.nlm.nih.gov/pubmed/28780013">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3651 href="https://doi.org/10.1053/j.gastro.2017.07.032">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732142605"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3660 class=n-a></a>Hyams JS, Chan D, Adedokun OJ, <i> et al.</i>: Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(12): 2227–37. <a target=xrefwindow id=d18144e3671 href="http://www.ncbi.nlm.nih.gov/pubmed/29140944">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3674 href="https://doi.org/10.1097/MIB.0000000000001262">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732142605">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732535720"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3687 class=n-a></a>Pastore S, Naviglio S, Canuto A, <i> et al.</i>: Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. <i>Paediatr Drugs.</i> 2018; <b>20</b>(2): 165–71. <a target=xrefwindow id=d18144e3698 href="http://www.ncbi.nlm.nih.gov/pubmed/29214394">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3701 href="https://doi.org/10.1007/s40272-017-0267-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732535720">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727309453"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3714 class=n-a></a>Hyams JS, Dubinsky MC, Baldassano RN, <i> et al.</i>: Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. <i>Gastroenterology.</i> 2017; <b>152</b>(8): 1901–1914.e3. <a target=xrefwindow id=d18144e3725 href="http://www.ncbi.nlm.nih.gov/pubmed/28193515">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3728 href="https://doi.org/10.1053/j.gastro.2017.02.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727309453">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732092122"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3741 class=n-a></a>Lemaitre M, Kirchgesner J, Rudnichi A, <i> et al.</i>: Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. <i>JAMA</i> 2017; <b>318</b>(17): 1679–1686. <a target=xrefwindow id=d18144e3752 href="http://www.ncbi.nlm.nih.gov/pubmed/29114832">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3755 href="https://doi.org/10.1001/jama.2017.16071">Publisher Full Text </a> | <a target=xrefwindow id=d18144e3759 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5818785">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732092122">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727350170"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3772 class=n-a></a>Eickstaedt JB, Killpack L, Tung J, <i> et al.</i>: Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. <i>Pediatr Dermatol.</i> 2017; <b>34</b>(3): 253–260. <a target=xrefwindow id=d18144e3783 href="http://www.ncbi.nlm.nih.gov/pubmed/28211161">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3786 href="https://doi.org/10.1111/pde.13081">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727350170">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d18144e3800 class=n-a></a>Jacobstein DA, Markowitz JE, Kirschner BS, <i> et al.</i>: Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium. <i>Inflamm Bowel Dis.</i> 2005; <b>11</b>(5): 442–6. <a target=xrefwindow id=d18144e3811 href="http://www.ncbi.nlm.nih.gov/pubmed/15867583">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3814 href="https://doi.org/10.1097/01.mib.0000158166.88238.ea">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d18144e3823 class=n-a></a>Cozijnsen MA, Escher JC, Griffiths A, <i> et al.</i>: Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. <i>Inflamm Bowel Dis.</i> 2015; <b>21</b>(4): 951–61. <a target=xrefwindow id=d18144e3834 href="http://www.ncbi.nlm.nih.gov/pubmed/25723615">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3837 href="https://doi.org/10.1097/MIB.0000000000000245">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2953958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3846 class=n-a></a>Colombel JF, Sandborn WJ, Reinisch W, <i> et al.</i>: Infliximab, azathioprine, or combination therapy for Crohn's disease. <i>N Engl J Med.</i> 2010; <b>362</b>(15): 1383–95. <a target=xrefwindow id=d18144e3857 href="http://www.ncbi.nlm.nih.gov/pubmed/20393175">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3860 href="https://doi.org/10.1056/NEJMoa0904492">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2953958">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734101636"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3873 class=n-a></a>Colombel JF, Adedokun OJ, Gasink C, <i> et al.</i>: Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(8): 1525–1532.e1. <a target=xrefwindow id=d18144e3884 href="http://www.ncbi.nlm.nih.gov/pubmed/30267864">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3887 href="https://doi.org/10.1016/j.cgh.2018.09.033">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734101636">F1000 Recommendation</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d18144e3900 class=n-a></a>Terdiman JP, Gruss CB, Heidelbaugh JJ, <i> et al.</i>: American Gastroenterological Association Institute guideline on the Use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology.</i> 2013; <b>145</b>(6): 1459–63. <a target=xrefwindow id=d18144e3911 href="http://www.ncbi.nlm.nih.gov/pubmed/24267474">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3914 href="https://doi.org/10.1053/j.gastro.2013.10.047">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d18144e3923 class=n-a></a>Kierkuś J, Iwańczak B, Wegner A, <i> et al.</i>: Monotherapy With Infliximab Versus Combination Therapy in the Maintenance of Clinical Remission in Children With Moderate to Severe Crohn Disease. <i>J Pediatr Gastroenterol Nutr.</i> 2015; <b>60</b>(5): 580–5. <a target=xrefwindow id=d18144e3934 href="http://www.ncbi.nlm.nih.gov/pubmed/25564804">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3937 href="https://doi.org/10.1097/MPG.0000000000000684">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d18144e3947 class=n-a></a>Hyams JS, Ruemmele F, Colletti RB, <i> et al.</i>: Sa1153 Impact of Concomitant Immunosuppressant Use on Adalimumab Efficacy in Children With Moderately to Severely Active Crohn's Disease: Results From IMAgINE 1. <i>Gastroenterology.</i> 2014; <b>146</b>(5): S–214. <a target=xrefwindow id=d18144e3958 href="https://doi.org/10.1016/S0016-5085(14)60757-5">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1605956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e3967 class=n-a></a>Rosh JR, Lerer T, Markowitz J, <i> et al.</i>: Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. <i>Am J Gastroenterol.</i> 2009; <b>104</b>(12): 3042–9. <a target=xrefwindow id=d18144e3978 href="http://www.ncbi.nlm.nih.gov/pubmed/19724267">PubMed Abstract </a> | <a target=xrefwindow id=d18144e3981 href="https://doi.org/10.1038/ajg.2009.493">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1605956">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d18144e3994 class=n-a></a>Assa A, Hartman C, Weiss B, <i> et al.</i>: Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. <i>J Crohns Colitis.</i> 2013; <b>7</b>(5): 369–76. <a target=xrefwindow id=d18144e4005 href="http://www.ncbi.nlm.nih.gov/pubmed/22483567">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4008 href="https://doi.org/10.1016/j.crohns.2012.03.006">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d18144e4017 class=n-a></a>Nuti F, Viola F, Civitelli F, <i> et al.</i>: Biological therapy in a pediatric Crohn disease population at a referral center. <i>J Pediatr Gastroenterol Nutr.</i> 2014; <b>58</b>(5): 582–7. <a target=xrefwindow id=d18144e4028 href="http://www.ncbi.nlm.nih.gov/pubmed/24343280">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4031 href="https://doi.org/10.1097/MPG.0000000000000276">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d18144e4040 class=n-a></a>Gouldthorpe O, Catto-Smith AG, Alex G, <i> et al.</i>: Loss of response to long-term infliximab therapy in children with Crohn’s disease. <i>Pharmaceuticals (Basel).</i> 2013; <b>6</b>(10): 1322–34. <a target=xrefwindow id=d18144e4051 href="http://www.ncbi.nlm.nih.gov/pubmed/24275852">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4054 href="https://doi.org/10.3390/ph6101322">Publisher Full Text </a> | <a target=xrefwindow id=d18144e4058 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3817600">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d18144e4067 class=n-a></a>Vahabnezhad E, Rabizadeh S, Dubinsky MC: A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. <i>Inflamm Bowel Dis.</i> 2014; <b>20</b>(4): 606–13. <a target=xrefwindow id=d18144e4075 href="http://www.ncbi.nlm.nih.gov/pubmed/24552827">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4078 href="https://doi.org/10.1097/MIB.0000000000000003">Publisher Full Text </a> | <a target=xrefwindow id=d18144e4081 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5330671">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d18144e4091 class=n-a></a>Russell RK, Wilson ML, Loganathan S, <i> et al.</i>: A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. <i>Aliment Pharmacol Ther.</i> 2011; <b>33</b>(8): 946–53. <a target=xrefwindow id=d18144e4102 href="http://www.ncbi.nlm.nih.gov/pubmed/21342211">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4105 href="https://doi.org/10.1111/j.1365-2036.2011.04603.x">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d18144e4114 class=n-a></a>Church PC, Guan J, Walters TD, <i> et al.</i>: Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. <i>Inflamm Bowel Dis.</i> 2014; <b>20</b>(7): 1177–86. <a target=xrefwindow id=d18144e4125 href="http://www.ncbi.nlm.nih.gov/pubmed/24865777">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4128 href="https://doi.org/10.1097/MIB.0000000000000083">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d18144e4137 class=n-a></a>Grossi V, Lerer T, Griffiths A, <i> et al.</i>: Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn’s Disease. <i>Clin Gastroenterol Hepatol.</i> 2015; <b>13</b>(10): 1748–56. <a target=xrefwindow id=d18144e4148 href="http://www.ncbi.nlm.nih.gov/pubmed/25911120">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4151 href="https://doi.org/10.1016/j.cgh.2015.04.010">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d18144e4160 class=n-a></a>Yarur AJ, Jain A, Hauenstein SI, <i> et al.</i>: Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(2): 409–15. <a target=xrefwindow id=d18144e4171 href="http://www.ncbi.nlm.nih.gov/pubmed/26752470">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4174 href="https://doi.org/10.1097/MIB.0000000000000689">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732234887"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4183 class=n-a></a>Day AS, Gulati AS, Patel N, <i> et al.</i>: The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr.</i> 2018; <b>66</b>(2): 361–8. <a target=xrefwindow id=d18144e4194 href="http://www.ncbi.nlm.nih.gov/pubmed/29210919">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4197 href="https://doi.org/10.1097/MPG.0000000000001850">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732234887">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d18144e4210 class=n-a></a>Beaugerie L, Brousse N, Bouvier AM, <i> et al.</i>: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Lancet.</i> 2009; <b>374</b>(9701): 1617–25. <a target=xrefwindow id=d18144e4221 href="http://www.ncbi.nlm.nih.gov/pubmed/19837455">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4224 href="https://doi.org/10.1016/S0140-6736(09)61302-7">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d18144e4234 class=n-a></a>Kotlyar DS, Blonski W, Diamond RH, <i> et al.</i>: Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. <i>Am J Gastroenterol.</i> 2010; <b>105</b>(10): 2299–301. <a target=xrefwindow id=d18144e4245 href="http://www.ncbi.nlm.nih.gov/pubmed/20927075">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4248 href="https://doi.org/10.1038/ajg.2010.213">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d18144e4257 class=n-a></a>Kotlyar DS, Osterman MT, Diamond RH, <i> et al.</i>: A systematic review of factors that contribute to hepatosplenic T-Cell lymphoma in patients with inflammatory bowel disease. <i>Clin Gastroenterol Hepatol.</i> 2011; <b>9</b>(1): 36–41.e1. <a target=xrefwindow id=d18144e4268 href="http://www.ncbi.nlm.nih.gov/pubmed/20888436">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4271 href="https://doi.org/10.1016/j.cgh.2010.09.016">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d18144e4280 class=n-a></a>Armuzzi A, Felice C: Natalizumab in Crohn's disease: past and future areas of applicability. <i>Ann Gastroenterol.</i> 2013; <b>26</b>(3): 189–190. <a target=xrefwindow id=d18144e4288 href="http://www.ncbi.nlm.nih.gov/pubmed/24714373">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4291 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3959451">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734448590"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4300 class=n-a></a>Chudy-Onwugaje KO, Christian KE, Farraye FA, <i> et al.</i>: A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. <i>Inflamm Bowel Dis.</i> 2019; <b>25</b>(5): 820–830. <a target=xrefwindow id=d18144e4311 href="http://www.ncbi.nlm.nih.gov/pubmed/30445504">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4314 href="https://doi.org/10.1093/ibd/izy327">Publisher Full Text </a> | <a target=xrefwindow id=d18144e4318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6468492">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734448590">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d18144e4331 class=n-a></a>Hyams JS, Wilson DC, Thomas A, <i> et al.</i>: Natalizumab therapy for moderate to severe Crohn disease in adolescents. <i>J Pediatr Gastroenterol Nutr.</i> 2007; <b>44</b>(2): 185–91. <a target=xrefwindow id=d18144e4342 href="http://www.ncbi.nlm.nih.gov/pubmed/17255829">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4345 href="https://doi.org/10.1097/01.mpg.0000252191.05170.e7">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d18144e4354 class=n-a></a>Singh N, Deshpande R, Rabizadeh S, <i> et al.</i>: Real World Experience With Natalizumab at a Tertiary Care Pediatric IBD Center. <i>J Pediatr Gastroenterol Nutr.</i> 2016; <b>62</b>(6): 863–6. <a target=xrefwindow id=d18144e4365 href="http://www.ncbi.nlm.nih.gov/pubmed/27213249">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4368 href="https://doi.org/10.1097/MPG.0000000000001089">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d18144e4378 class=n-a></a>Mosli MH, MacDonald JK, Bickston SJ, <i> et al.</i>: Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis. <i>Inflamm Bowel Dis.</i> 2015; <b>21</b>(5): 1151–9. <a target=xrefwindow id=d18144e4389 href="http://www.ncbi.nlm.nih.gov/pubmed/25844963">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4392 href="https://doi.org/10.1097/MIB.0000000000000396">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718083272"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4401 class=n-a></a>Sandborn WJ, Feagan BG, Rutgeerts P, <i> et al.</i>: Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>N Engl J Med.</i> 2013; <b>369</b>(8): 711–21. <a target=xrefwindow id=d18144e4412 href="http://www.ncbi.nlm.nih.gov/pubmed/23964933">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4415 href="https://doi.org/10.1056/NEJMoa1215739">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718083272">F1000 Recommendation</a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718083273"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4428 class=n-a></a>Feagan BG, Rutgeerts P, Sands BE, <i> et al.</i>: Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>N Engl J Med.</i> 2013; <b>369</b>(8): 699–710. <a target=xrefwindow id=d18144e4439 href="http://www.ncbi.nlm.nih.gov/pubmed/23964932">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4442 href="https://doi.org/10.1056/NEJMoa1215734">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718083273">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726749172"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4455 class=n-a></a>Feagan BG, Rubin DT, Danese S, <i> et al.</i>: Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clin Gastroenterol Hepatol.</i> 2017; <b>15</b>(2): 229–239.e5. <a target=xrefwindow id=d18144e4466 href="http://www.ncbi.nlm.nih.gov/pubmed/27639327">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4469 href="https://doi.org/10.1016/j.cgh.2016.08.044">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726749172">F1000 Recommendation</a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733362483"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4482 class=n-a></a>Feagan BG, Lasch K, Lissoos T, <i> et al.</i>: Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(1): 130–138.e7. <a target=xrefwindow id=d18144e4493 href="http://www.ncbi.nlm.nih.gov/pubmed/29857145">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4496 href="https://doi.org/10.1016/j.cgh.2018.05.026">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733362483">F1000 Recommendation</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d18144e4509 class=n-a></a>Conrad MA, Stein RE, Maxwell EC, <i> et al.</i>: Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(10): 2425–31. <a target=xrefwindow id=d18144e4520 href="http://www.ncbi.nlm.nih.gov/pubmed/27598742">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4523 href="https://doi.org/10.1097/MIB.0000000000000918">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737021311"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4533 class=n-a></a>Hamel B, Wu M, Hamel EO, <i> et al.</i>: Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis. <i>BMJ Open Gastroenterol.</i> 2018; <b>5</b>(1): e000195. <a target=xrefwindow id=d18144e4544 href="http://www.ncbi.nlm.nih.gov/pubmed/29527316">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4547 href="https://doi.org/10.1136/bmjgast-2017-000195">Publisher Full Text </a> | <a target=xrefwindow id=d18144e4551 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5841492">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737021311">F1000 Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727715252"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4564 class=n-a></a>Ledder O, Assa A, Levine A, <i> et al.</i>: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. <i>J Crohns Colitis.</i> 2017; <b>11</b>(10): 1230–7. <a target=xrefwindow id=d18144e4575 href="http://www.ncbi.nlm.nih.gov/pubmed/28605483">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4578 href="https://doi.org/10.1093/ecco-jcc/jjx082">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727715252">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d18144e4591 class=n-a></a>Singh N, Rabizadeh S, Jossen J, <i> et al.</i>: Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. <i>Inflamm Bowel Dis.</i> 2016; <b>22</b>(9): 2121–6. <a target=xrefwindow id=d18144e4602 href="http://www.ncbi.nlm.nih.gov/pubmed/27542130">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4605 href="https://doi.org/10.1097/MIB.0000000000000865">Publisher Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734023680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4614 class=n-a></a>Schneider AM, Weghuber D, Hetzer B, <i> et al.</i>: Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. <i>BMC Gastroenterol.</i> 2018; <b>18</b>(1): 140. <a target=xrefwindow id=d18144e4625 href="http://www.ncbi.nlm.nih.gov/pubmed/30219028">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4628 href="https://doi.org/10.1186/s12876-018-0868-x">Publisher Full Text </a> | <a target=xrefwindow id=d18144e4632 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6139155">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734023680">F1000 Recommendation</a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735101435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4645 class=n-a></a>Plevris N, Chuah CS, Allen RM, <i> et al.</i>: Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. <i>J Crohns Colitis.</i> 2019; <b>13</b>(9): 1111–20. <a target=xrefwindow id=d18144e4656 href="http://www.ncbi.nlm.nih.gov/pubmed/30768123">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4659 href="https://doi.org/10.1093/ecco-jcc/jjz042">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735101435">F1000 Recommendation</a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d18144e4672 class=n-a></a>Dulai PS, Singh S, Jiang X, <i> et al.</i>: The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>Am J Gastroenterol.</i> 2016; <b>111</b>(8): 1147–55. <a target=xrefwindow id=d18144e4683 href="http://www.ncbi.nlm.nih.gov/pubmed/27296941">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4686 href="https://doi.org/10.1038/ajg.2016.236">Publisher Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d18144e4696 class=n-a></a>Vermeire S, O'Byrne S, Keir M, <i> et al.</i>: Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet.</i> 2014; <b>384</b>(9940): 309–18. <a target=xrefwindow id=d18144e4707 href="http://www.ncbi.nlm.nih.gov/pubmed/24814090">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4710 href="https://doi.org/10.1016/S0140-6736(14)60661-9">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727003797"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4719 class=n-a></a>Feagan BG, Sandborn WJ, Gasink C, <i> et al.</i>: Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>N Engl J Med.</i> 2016; <b>375</b>(20): 1946–60. <a target=xrefwindow id=d18144e4730 href="http://www.ncbi.nlm.nih.gov/pubmed/27959607">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4733 href="https://doi.org/10.1056/NEJMoa1602773">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727003797">F1000 Recommendation</a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733463140"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4746 class=n-a></a>Rutgeerts P, Gasink C, Chan D, <i> et al.</i>: Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease. <i>Gastroenterology.</i> 2018; <b>155</b>(4): 1045–58. <a target=xrefwindow id=d18144e4757 href="http://www.ncbi.nlm.nih.gov/pubmed/29909019">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4760 href="https://doi.org/10.1053/j.gastro.2018.06.035">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733463140">F1000 Recommendation</a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d18144e4773 class=n-a></a>Rinawi F, Rosenbach Y, Assa A, <i> et al.</i>: Ustekinumab for Resistant Pediatric Crohn Disease. <i>J Pediatr Gastroenterol Nutr.</i> 2016; <b>62</b>(4): e34–5. <a target=xrefwindow id=d18144e4784 href="http://www.ncbi.nlm.nih.gov/pubmed/25023579">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4787 href="https://doi.org/10.1097/MPG.0000000000000503">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d18144e4796 class=n-a></a>Bishop C, Simon H, Suskind D, <i> et al.</i>: Ustekinumab in Pediatric Crohn Disease Patients. <i>J Pediatr Gastroenterol Nutr.</i> 2016; <b>63</b>(3): 348–51. <a target=xrefwindow id=d18144e4807 href="http://www.ncbi.nlm.nih.gov/pubmed/26854655">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4810 href="https://doi.org/10.1097/MPG.0000000000001146">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d18144e4819 class=n-a></a>Dayan JR, Dolinger M, Benkov K, <i> et al.</i>: Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center. <i>J Pediatr Gastroenterol Nutr.</i> 2019; <b>69</b>(1): 61–67. <a target=xrefwindow id=d18144e4830 href="http://www.ncbi.nlm.nih.gov/pubmed/31058718">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4833 href="https://doi.org/10.1097/MPG.0000000000002362">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d18144e4843 class=n-a></a>Coskun M, Salem M, Pedersen J, <i> et al.</i>: Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. <i>Pharmacol Res.</i> 2013; <b>76</b>: 1–8. <a target=xrefwindow id=d18144e4854 href="http://www.ncbi.nlm.nih.gov/pubmed/23827161">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4857 href="https://doi.org/10.1016/j.phrs.2013.06.007">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d18144e4866 class=n-a></a>Friedman S: Tofacitinib for Ulcerative Colitis - A Promising Step Forward. <i>N Engl J Med.</i> 2017; <b>376</b>(18): 1792–3. <a target=xrefwindow id=d18144e4874 href="http://www.ncbi.nlm.nih.gov/pubmed/28467881">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4877 href="https://doi.org/10.1056/NEJMe1701505">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727629246"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4886 class=n-a></a>Flamant M, Rigaill J, Paul S, <i> et al.</i>: Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects. <i>Drugs.</i> 2017; <b>77</b>(10): 1057–68. <a target=xrefwindow id=d18144e4897 href="http://www.ncbi.nlm.nih.gov/pubmed/28523588">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4900 href="https://doi.org/10.1007/s40265-017-0755-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727629246">F1000 Recommendation</a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727577400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4913 class=n-a></a>Sandborn WJ, Su C, Sands BE, <i> et al.</i>: Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>N Engl J Med.</i> 2017; <b>376</b>(18): 1723–36. <a target=xrefwindow id=d18144e4924 href="http://www.ncbi.nlm.nih.gov/pubmed/28467869">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4927 href="https://doi.org/10.1056/NEJMoa1606910">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727577400">F1000 Recommendation</a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733651824"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4940 class=n-a></a>Hanauer S, Panaccione R, Danese S, <i> et al.</i>: Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(1): 139–47. <a target=xrefwindow id=d18144e4951 href="http://www.ncbi.nlm.nih.gov/pubmed/30012431">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4954 href="https://doi.org/10.1016/j.cgh.2018.07.009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733651824">F1000 Recommendation</a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727120950"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d18144e4967 class=n-a></a>Vermeire S, Schreiber S, Petryka R, <i> et al.</i>: Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. <i>Lancet.</i> 2017; <b>389</b>(10066): 266–75. <a target=xrefwindow id=d18144e4978 href="http://www.ncbi.nlm.nih.gov/pubmed/27988142">PubMed Abstract </a> | <a target=xrefwindow id=d18144e4981 href="https://doi.org/10.1016/S0140-6736(16)32537-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727120950">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2097/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2097/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA<br/> <p> <div class=margin-bottom> Bhaskar Gurram <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ashish S. Patel <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-2097/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 13 Dec 2019, 8:2097 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19609.1">https://doi.org/10.12688/f1000research.19609.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Gurram B and Patel AS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=21500 data-id=19609 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19609.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-2097/v1/pdf?article_uuid=03cdc746-d4bb-4805-a109-536e81f749e6" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19609.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Gurram B and Patel AS. Recent advances in understanding and managing pediatric inflammatory bowel disease [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2097 (<a href="https://doi.org/10.12688/f1000research.19609.1" target=_blank>https://doi.org/10.12688/f1000research.19609.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19609 id=mobile-track-article-signin-19609 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19609?target=/articles/8-2097/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21500 /> <input name=articleId type=hidden value=19609 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Jaroslaw Kierkus</strong>, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children's Memorial Health Institute, Poland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Athos Bousvaros</strong>, Department of Medicine, Boston Children's Hospital, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Naamah Zitomersky</strong>, Department of Medicine, Boston Children's Hospital, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2097/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2097/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61224-57537></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61223-57538></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-2097/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>13 Dec 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jaroslaw Kierkus</strong>, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children's Memorial Health Institute, Poland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Athos Bousvaros</strong>, Department of Medicine, Boston Children's Hospital, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Naamah Zitomersky</strong>, Department of Medicine, Boston Children's Hospital, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-2097/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-2097/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding and managing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-2097/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-2097/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-2097/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Gurram B and Patel AS');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-2097/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-2097",
            templates : {
                twitter : "Recent advances in understanding and managing pediatric inflammatory.... Gurram B and Patel AS, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-2097/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding and managing pediatric inflammatory bowel disease", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding and managing pediatric inflammatory bowel disease", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19609/21500")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "21500");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "57537": 0,
                           "57538": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "2d0f2c5d-3581-4b11-b161-7f2ee98bc76b";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2097.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2097.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2097.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-2097.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-2097.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>